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Whilst antiretroviral drugs (ARVs) have significantly improved treatment of Human 
Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome (HIV and AIDS), 
several limitations exist with their oral route of administration. Several orally administered ARVs 
such as, didanosine, saquinavir, tenofovir and zidovudine are associated with low and erratic 
bioavailability due to extensive first pass effect (FPE) as well as gastrointestinal (GI) acids and 
enzymatic degradation.  Moreover, the half-life for several ARV drugs is short, which requires 
frequent administration of doses leading to systemic side effects and decreased patient 
compliance. Alternative routes of administration, such as buccal, rectal and vaginal, are widely 
investigated in the literature. Buccal delivery of drugs may therefore overcome the above 
limitations by bypassing FPE and GI degradation, thus improving bioavailability. Furthermore, 
drug absorption following buccal administration is not influenced by the potential variations in 
the gastric emptying rate or the presence of food.  However, drug absorption can be limited by 
low buccal permeability due to the epithelial lining the mucosa. Identifying optimal novel 
enhancers is paramount to designing and developing drugs as buccal delivery systems. In an 
attempt to explore the potential of the buccal mucosal route for the delivery of an ARV drug 
using didanosine (ddI) as a model drug, the aims of this study were to: 1] investigate the 
permeability properties of ddI across the buccal mucosa route in order to determine its 
suitability for development as a buccal delivery system, 2] determine the effects of novel 
permeation enhancers, i.e. aloe vera gel (AVgel), oleic acid (OA) and its novel synthesized 
oleodendrimer derivatives, on the buccal permeability of ddI, and 3] to find out (through histo-
morphological evaluation) whether  ddI and the novel enhancers, i.e. AV gel and novel OA 
derivatives have any toxic effects on the buccal mucosa.   
 
The buccal mucosa was harvested from pigs, and all the excess connective tissue was 
surgically removed. In vitro buccal permeation experiments were undertaken using modified 
vertical Franz diffusion cells, with phosphate buffered saline pH 7.4 (PBS) at 37 °C. ddI was 
quantified at 250 nm using a validated UV spectrophotometric method. The histomorphological 
evaluations were undertaken using light microscopy (LM) and transmission electron 
microscopy (TEM).  
 
ddI permeated through the buccal mucosa and its permeability was concentration-dependent. 
A linear relationship (R2 = 0.9557) between the concentrations and flux indicated passive 
diffusion as the mechanism of drug transport. AVgel, at concentrations of 0.25 to 2 %w/v, 
significantly enhanced ddI flux (p<0.05), with permeability enhancement ratios from 5.09 (0.25 
%w/v) to 11.78 (2 %w/v), but decreased permeability at 4 and 6 %w/v. OA and its derivatives, 
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i.e. ester (OA1E), the dicarboxylic acid (OA1A), the bicephalous dianionic surfactant (OA1ANa) 
and their parent compound, OA, all enhanced the buccal permeability of ddI. OA, OA1E, OA1A 
and OA1ANa at 1 %w/w all showed potential, with enhancement ratios (ER) of 1.29, 1.33, 1.01 
and 1.72 respectively. OA1ANa at 1 %w/w demonstrated the highest flux (80.30 ± 10.37 µg 
cm -2.hr), permeability coefficient (4.01 ± 0.57 x 10 -3 cm hr-1) and enhancement ratio (1.72). 
The highest flux for ddI (144.00 ± 53.54 µg cm -2.hr) was reported with OA1ANa at 2 %w/w, 
which displayed an ER of 3.09 more than that with ddI alone (p=0.0014). At equivalent 
concentrations, OA1ANa (ER=3.09) had a significantly higher permeation enhancing effect 
than its parent OA (ER=1.54).  
 
Histomorphological studies showed that ddI did not have any adverse effects on the buccal 
mucosae. Ultrastructural analysis of the buccal mucosae treated with phosphate buffer saline 
pH 7.4 (PBS), ddI/PBS and ddI/PBS/AVgel 0.5 %w/v showed cells with normal plasmalemma, 
well-developed cristae and nuclei with regular nuclear envelopes. However, cells from 1, 2 and 
6 %w/v AVgel-treated mucosae showed irregular nuclear outlines, increased intercellular 
spacing and plasmalemma crenulations. AVgel enhanced the buccal permeation of ddI and 
0.05 %w/v was identified as a potentially safe and effective concentration for developing and 
optimizing buccal delivery systems. OA1ANa at all concentrations, except 6.0 %w/w had no 
adverse effects on the mucosae. OA1ANa at 2 %w/w was identified as a potentially safe 
concentration, and the optimal novel OA derivative that can widen the pool of fatty acid 
derivatives as chemical permeation enhancers for buccal drug delivery. The cellular changes, 
such as vacuoles formation and increased intercellular spaces, were attributed to the buccal 
permeation enhancing effects of AVgel and OA1ANa. 
 
The results in this study confirmed the potential of buccal delivery of ddI, identified permeability 
parameters of ddI across the buccal mucosa and its permeability enhancement by both AVgel 
and OA derivatives as novel permeation enhancers. The study showed that both OA1ANa at 
2 %w/w and AVgel at 0.5 %w/v, or lower concentrations, can be used as buccal permeation 
enhancers to develop and optimize novel buccal delivery systems for ddI to improve ARV 
therapy. The novel enhancers are recommended for selection as buccal permeation 
enhancers, to design and optimize ddI buccal delivery systems, and application to other ARV 
drugs for improved therapy. 
 
Keywords: HIV and AIDS, Antiretroviral drugs, Buccal, Didanosine, Permeation enhancer, 
Aloe vera (L.) Burm. F. (Aloe barbadensis Miller), Oleic acid derivatives, Histomorphology, 
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The background to the studies presented in the thesis is described in this 
chapter.  The potential of the buccal mucosa route to address the limitations of 
other routes of administration are highlighted. It outlines the epithelium lining 
of mucosa as the barrier to drug permeation and proposes strategies to 
address this. It also describes aloe vera gel (AVgel) as a permeation enhancer 
from natural product origin and derivatives of fatty acids as chemical 
permeation enhancers (CPE). The aim and the objectives of the study, its 




This section presents a quick overview of buccal delivery and applicability to 
various drugs and disease conditions. The strategies to enhance permeation 
of drugs across the buccal mucosa including the use of permeation enhancers 
was highlighted. Further, the status of HIV and AIDS, the challenges of current 








1.2.1 BUCCAL DELIVERY 
While the oral route is convenient and remains the most popular and preferred 
route of drug administration by both patients and healthcare practitioners, it has 
several disadvantages (Morales and McConville, 2014; Sattar et al., 2014; Sohi 
et al., 2010). These include degradation of drugs due to acid and enzymatic 
attack in the gastrointestinal (GI) tract, as well as susceptibility to first pass 
hepatic metabolism, thereby reducing drug bioavailability and necessitating 
higher doses for administration (Desai et al., 2012). A major area of research 
is therefore seeking alternative routes of drug delivery, such as transdermal 
(Chen et al., 2013; Lam and Gambari, 2014; Patel et al., 2012a), buccal 
(Morales et al., 2013; Senel et al., 2012; Zeng et al., 2014) and vaginal (Berginc 
et al., 2014; D'Cruz and Uckun, 2014; Ghosal et al., 2014; Ndesendo et al., 
2008). 
 
The buccal route is receiving increasing interest, as it is an attractive alternate 
and non-invasive site for delivering both locally and systemically active drugs 
(Dhiman et al., 2009; Teubl et al., 2013). Drug in a dosage form, such as films, 
patches and gels, is applied and adheres to the mucosa lining, the inner cheeks 
of the mouth, where drug is absorbed (Hearnden et al., 2012; Patel et al., 
2011). The buccal mucosal route has several advantages. It avoids the 
degradation of drugs by both the GI acids and enzymes and bypasses hepatic 
first pass metabolism, thereby improving the systemic bioavailability of various 
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drugs (Madhav et al., 2012; Singh, 2013). Furthermore, absorption following 
administration via the buccal route is not influenced by potential variations in 
the gastric emptying rate or the presence of food (Li and Chan, 1999; 
MacBrayne et al., 2014). The permeability of the buccal mucosa is also higher 
than that of the skin (Patel et al., 2011), and a lower loading dose in a 
transbuccal device could provide the same therapeutic effect as a transdermal 
patch.  
 
Moreover, the buccal mucosa has a larger area for drug application, and has 
good accessibility compared to other mucosae, such as the nasal, rectal and 
vaginal (das Neves et al., 2011; Mallipeddi and Rohan, 2010; Ndesendo et al., 
2008). In addition there is increased ease of dosage form application and easy 
removal if therapy is required to be discontinued. Various classes of drugs, 
including antiretroviral (zalcitabine (ddC), tenofovir (TFV), and saquinavir 
(SQV)) (Rambharose et al., 2014b; Shojaei et al., 1999; Xiang et al., 2002), 
non-steroidal anti-inflammatory) (piroxicam) (Attia et al., 2004), opiate 
(morphine) (Senel et al., 1997), proton-pump inhibitor (omeprazole) (Figueiras 
et al., 2010), anti-diabetic hormone and blood glucose lowering 
agent(insulin)(Morales et al., 2014; Xue et al., 2012)  and (beta blocker) (e.g. 
metoprolol) (Patel et al., 2012b), have been studied for delivery via the buccal 
mucosa to exploit its above advantages. The buccal route therefore has wide 







Some disadvantages include:  
1) the buccal epithelium lining the mucosa is a barrier to drug permeation 
which reduces the bioavailability of drugs applied via the buccal route 
(Hearnden et al., 2012).  
2) the bucal mucosa is largely hindered by the thickness of mucus 
viscoelastic layer and a continuous secretion of the saliva which may 
potentially lead to drug dilution, lowered drug concentration, and reduced 
bioavailability (Madhav et al., 2009).  
3) the chewing and swallowing of food can potentially lead to drug loss due 
to involuntary removal and swallowing of the dosage form and drugs from 
the application site as well as may cause possible hazard of choking 
(Heemstra et al., 2010).  
 
However, these disadvantages are superseded by the advantages, and the 
delivery of drugs via the oral mucosal route and modification of dosage forms 
are currently a major focus of international pharmaceutical science research 
for enhancing drug therapy.  Studies on buccal delivery will contribute to 
developing cost-effective dosage forms, leading to an improved disease 
management, improved quality of life, and ultimately a reduction in health care 
costs both in South Africa and internationally.  An improved economy at a 
global level is expected with improved drug therapy, as better drug treatment 
will lead to a reduction in work absenteeism, promote better work output and 
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general health state of the global community. Therefore, strategies to enhance 
the formulation and properties of buccal delivery systems are essential.  
 
1.2.2 PERMEATION ENHANCEMENT STRATEGIES FOR BUCCAL 
DRUG DELIVERY 
One of the main challenges with buccal mucosal therapy is its limited mucosal 
permeability due to the epithelial lining of the membrane which acts as a barrier 
to drug permeation (Giannola et al., 2007; Sattar et al., 2014; Şenel and Hıncal, 
2001; Teubl et al., 2013). The outermost layer of the stratified squamous 
epithelium is non-keratinized, covered by a thin layer of mucus and is 
comparatively thicker than the rest of the oral mucosal lining. The basement 
membrane lies directly underneath the epithelium, followed by the lamina 
propria and the submucosa. The mucosa is made up of about 40-50 cell layers 
and a thickness of 500–800 µm has been reported (Dodla and Velmurugan, 
2013; Pather et al., 2008). The mucosal structure thus contributes to the 
challenges and factors that are responsible for the limited buccal permeability 
of drugs.  Enhancing permeation of drugs across the buccal mucosa is 
therefore critical for optimizing bioavailability of various drugs (Hearnden et al., 
2012; Madhav et al., 2012).  
 
Maximizing the bioavailability of several drugs after buccal administration for 
absorption through the mucosal lining will be beneficial to reducing intra and 
inter subject variability as well as side effects of the drugs (Kapil et al., 2013; 
Patel et al., 2012b). Moreover, the cost of manufacture will be reduced by 
  
 7 
decreasing drug wastage owing to its low systemic bioavailability (Aungst, 
2012), especially where drugs have limited permeability and subsequently low 
bioavailability. Hence, the use of permeation enhancing strategies in many 
cases is essential to overcome the limited permeability of the buccal mucosae 
for improved buccal drug delivery (Hassan et al., 2010; Senel et al., 2012; Sohi 
et al., 2010).   
 
Approaches to promote buccal permeation of drugs thus include the use of 
chemical permeation enhancers and physical methods, such as particle size 
reduction by ball milling (Hu et al., 2011a; Hu et al., 2011b; Rambharose et al., 
2014a; Rao et al., 2011). Other approaches include ultrasound and electrical 
assisted methods (iontophoresis and electroporation), as well as thermal 
enhancement (Morales and McConville, 2014; Senel et al., 2012; Wei et al., 
2012). A buccal delivery system that employs a permeation enhancer to deliver 
insulin is commercially available. The system uses bile salts encapsulated as 
an enhancer in mixed micelles for improved hypoglycaemic therapy (Palermo 
et al., 2011). There is therefore a scope to develop buccal drug delivery 
systems to utilize permeation enhancers for improved buccal drug delivery. 
 
1.2.3 PERMEATION ENHANCERS FOR BUCCAL DELIVERY  
Permeation enhancers are substances or techniques that are widely used in 
promoting the permeability of drugs across mucosal membranes including 
buccal mucosa. Chemical permeation enhancers (CPEs) have been employed 
and proved promising for enhancing permeability of various drugs (Hassan et 
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al., 2010; Sohi et al., 2010). Examples include bile salts, fatty acids and 
surfactants, i.e. sodium deoxycholate for 5-FU (Pendekal and Tegginamat, 
2012), oleic acid for clonazepam (Sakata et al., 2011) and sodium dodecyl 
sulfate for insulin, caffeine and estradiol (Bernstein, 2008; Nicolazzo et al., 
2004). The discovery of new permeation enhancers and the careful selection 
for buccal permeability enhancement of drugs are essential to optimize drug 
delivery via the buccal route.  
 
1.2.3.1 ALOE VERA GEL  
Currently, there is an increasing interest in drug products that either are of 
natural origin or contain components of natural products. Permeation 
enhancers from natural origin have become popular as they offer numerous 
benefits over their synthetic counterparts. These benefits include sustainable 
mass production from renewable resources as well as lower cost of production 
depending on the extraction method used (Fox et al., 2011; Maurya et al., 2006; 
Rodríguez-González et al., 2012). 
 
Aloe vera (Aloe barbadensis Miller) is a succulent plant with strap-shaped 
green leaves (Kiran and Rao, 2014; Lad and Murthy, 2013). The aloe latex (or 
exudate), the aloe gel and the whole leaf (or whole leaf extract) are the main 
parts used for medicinal applications (Chen et al., 2009). The inner pulp of the 
fresh leaves is used for gel extrusion (Hamman, 2008; Reynolds and Dweck, 
1999).  The gel obtained from aloe vera, i.e. aloe vera gel (AVgel), is composed 
mainly of water (>99 %), and the remaining 0.5 – 1 % of solid material 
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comprises several polysaccharides, vitamins, enzymes, lipids, inorganic and 
small organic compounds (Boudreau and Beland, 2006). Additional properties 
identified for Aloe vera are anti-inflammatory and antifungal, as well as soothing 
effect on the mucosal lining and wound healing properties (Pugh et al., 2001). 
While AVgel has been shown to be an effective transdermal (Cole and Heard, 
2007) and intestinal (Chen et al., 2009) permeation enhancer for various drugs, 
its applicability for buccal permeation enhancement has not been previously 
investigated. In addition, those studies with AVgel as an enhancer for the 
intestinal and transdermal routes did not report its histomorphological effects 
(Chen et al., 2009; Cole and Heard, 2007), which is important for assessing its 
preliminary suitability.  
In the in vitro permeation studies reported by Chen et al 2009, it was reported 
that the polysaccharides from Aloe vera gel is capable of reducing the TEER 
of excised rat intestinal tissue, thus enhancing the transport of atenolol across 
this tissue to a significant extent. Moreover, Aloe vera gel materials could 
significantly decrease the TEER of Caco-2 cell monolayers and this reduction 
in TEER was associated with the opening of tight junctions between adjacent 
epithelial cells and this effect was completely reversible after removal of the 
Aloe vera leaf materials from the cell monolayers.  
Cole and Heard (2007) also stated that the skin penetration enhancement 
effect of AVgel was due to a probable pull effect of complexes formed between 
the compound and the enhancing agent within the aloe gel, however, the 
proposed mechanism of action has to be further investigated and confirmed as 
stated by the authors. 
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Furthermore, the histomorphological studies could be useful for identifying the 
potential mechanisms of permeation enhancers and drug permeation 
pathways. 
Aloe vera gel has also been shown to have the potential to modify drug release 
profiles in pharmaceutical dosage forms (Jani et al., 2007). Moreover, 
polysaccharides form a major component of AVgel, therefore unlike several 
other existing permeation enhancers, it has the potential to also provide 
multifunctional properties in buccal drug delivery systems. Furthermore, aloe 
vera has been reported as useful to treat bacterial and fungal infections, as well 
as sexually transmitted diseases, including HIV and AIDS (Kamatenesi-
Mugisha et al., 2008; Pugh et al., 2001). It was therefore the focus of this study 
to explore the potential of AVgel in enhancing the buccal permeation of drugs, 




1.2.3.2 FATTY ACIDS DERIVATIVES 
Fatty Acids (FAs) are widely used chemical permeation enhancers for various 
drugs (Dodla and Velmurugan, 2013). For example, oleic acid, sodium caprate, 
caprylic acid, sucrose esters and lauric acid have been reported for enhancing 
the permeation of drugs such as propranolol, lidocaine, ergotamine, insulin and 
sumatriptan across the buccal mucosa (Artusi et al., 2004; Bhati, 2012; Bigucci 
et al., 2014; Senel and Hincal, 2001; Sohi et al., 2010; Tsutsumi et al., 1998). 
It has been reported that FAs can disrupt the lipid bilayer of the mucosal lining 
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thereby increasing drug transport and bioavailability (Dodla and Velmurugan, 
2013; Hassan et al., 2010; Sohi et al., 2010). Oleic acid (OA) in particular has 
been reported as an effective chemical permeation enhancer for drugs, such 
as levothyroxine sodium via the intestinal route (Pabla et al., 2010), caffeine 
and diclofenac sodium (DS) via the transdermal route (Ochalek et al., 2012), 
and propranolol as well as 5-fluorouracil via the buccal route (Bigucci et al., 
2014; Dhiman et al., 2009).  
 
Recent reports are emerging on the use of derivatives of common chemical 
enhancers for further maximising mucosal drug permeation (Caon et al., 2014; 
Hassan et al., 2010). For example, newly synthesised propanoyloxy derivatives 
of 5b-cholan-24-oic acid were more effective in enhancing permeation of 
theophylline as compared to its parent compound, cholic acid, thereby 
potentiating the efficacy of bile acids as a class of chemical permeation 
enhancers (Coufalová et al., 2013; Mrózek et al., 2013). There is therefore a 
need to explore and identify new derivatives of chemical enhancers to widen 
the pool of available superior enhancers for buccal drug delivery. Novel 
derivatives of OA will therefore be useful to further improve the permeation 
enhancing potential of fatty acids, and to contribute to the pool of enhancers 
for enhancing drug permeability.  
 
Synthesizing novel OA derivatives i.e. A1E, A2E, E1E and E2E of G1 and G2 
was reported for transdermal delivery of diclofenac sodium (DS), a non-
steroidal anti-inflammatory drug (Kalhapure and Akamanchi, 2013). 
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Oleodendrimers A1E and A2E have an amide linkage whereas, E1E and E2E 
have an ester linkage between the dendron and OA moiety. The derivatives of 
OA were shown to be more effective in enhancing the transdermal permeation 
of DS compared to the parent OA. The potential of these novel derivatives i.e. 
oleodendrimers as permeation enhancer for buccal delivery, have not been 
studied for any drug to date. The buccal permeation enhancement of these OA 
derivatives may expand its applicability in drug delivery systems. Investigating 
aloe vera gel and novel derivatives of fatty acids as buccal permeation 
enhancers remains to be explored. 
 
1.2.4 HIV AND AIDS AND CHALLENGES OF CURENT ARV THERAPY 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune 
Deficiency Syndrome (AIDS), remain a major health challenge in Africa and 
globally. It constitutes one of the most serious infectious disease challenges to 
public health globally, and has had a crippling effect in certain parts of the 
world, especially sub-Saharan Africa (Mazzeo et al., 2012). There are currently 
35.3 million people living with HIV and AIDS globally, of whom 25 million are in 
sub-Saharan Africa, and represent 71% of the global number. HIV and AIDS is 
therefore still the leading fatal disease worldwide  (UNAIDS, 2013; WHO, 
2013).  
 
While ARV drug therapy has contributed significantly to improved management 
of patients with HIV and AIDS, its current use is associated with several 
challenges and inconveniences (Boffito et al., 2014; Ramana et al., 2014). 
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Many ARV drugs undergo extensive first pass metabolism and gastrointestinal 
degradation leading to low and erratic bioavailability. The half-lives of several 
ARV drugs are short, which then requires frequent administration of doses, 
leading to dose-dependent side effects and decreased patient compliance (Li 
and Chan, 1999; MacBrayne et al., 2014; Rakhmanina et al., 2012).   
 
Despite the availability of ARV therapy, the above statistics indicate that much 
remains to be accomplished, as the number of newly reported HIV infections is 
still unacceptably high (UNAIDS, 2013). In addition to acid degradation and first 
pass hepatic metabolism, several ARV drugs suffer from physicochemical 
problems, such as poor solubility that may lead to formulation difficulties (Li and 
Chan, 1999; Xiang et al., 2002).  Strategies currently being investigated to 
overcome these limitations include: identifying new and chemical modification 
of existing chemical entities (Ghosh et al., 2008; Schroeder et al., 2014; Vivet-
Boudou et al., 2011), examining various dosing regimens (de Kock et al., 2014; 
Larson et al., 2014), designing and developing novel drug delivery systems 
(das Neves et al., 2010; Ramana et al., 2014; Sosnik et al., 2009) that can 
improve the efficacy of both existing and new ARV drugs.  Moreover, different 
routes of drug administration, including buccal (Jones et al., 2014; 
Rambharose, 2013; Xiang et al., 2002), rectal (das Neves et al., 2013; Dezzutti 
et al., 2014), and transdermal (van Heerden et al., 2010; Zidan and Habib, 






1.2.5 ANTIRETROVIRAL DRUGS FOR BUCCAL DELIVERY 
Drugs administered via the buccal route will avoid degradation by both the GI 
acids and enzymes, and will also bypass the hepatic first pass metabolism, 
thereby improving their bioavailability (Morales and McConville, 2011; Singh, 
2013). Buccal delivery will benefit most ARV drugs as it can address several 
disadvantages and challenges that exist with current ARV therapy, such as:  
  Most ARVs have low bioavailability due to hepatic first pass metabolism 
and their degradation in the acidic and enzymatic conditions of the 
gastrointestinal tract. Their absorption may also be influenced by 
variations in the gastric emptying rate as well as presence of food. The 
buccal route as an alternative to oral will bypass the hepatic first pass 
effect and the harsh conditions of the GI, thus improving the 
bioavailability of the ARVs (Desai et al., 2012).  
 Most ARVs have short half-lives that necessitate that higher doses be 
incorporated into the dosage forms, and that they be given frequently to 
treat HIV and AIDS. As a result of these higher and more frequent 
doses, patients experience severe dose-dependent systemic side and 
adverse effects, and may therefore not comply with ARV dosage 
regimens. Buccal route will require lesser amount of such drugs as 
compared to oral route, since the buccal mucosal site for the dosage 
application is highly vascularised, and can promote higher absorption of 
drugs. The dose-dependent toxicities and adverse effects experienced 
with ARV therapy will be significantly reduced and patient compliance 
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improved by using the buccal route (Chandwani et al., 2012; Hien et al., 
2013). 
 Most ARVs, due to their low bioavailability, are formulated as high-dose 
oral dosage forms which translate into larger oral delivery systems such 
as tablet. This presents with swallowing challenges in paediatrics as well 
as in adults with dysphagia. The amount of drug incorporated into a 
buccal delivery system is smaller compared to the amount of drug 
incorporated into an oral delivery system. The formulation of ARVs for 
buccal delivery may also exhibit controlled-release kinetics of drugs, 
which requires that drug release is prolonged at the site of application 
over a predetermined period of time.  The frequency of dosing as well 
as the systemic side effects are reduced, and patient compliance with 
their ARV therapy is improved (Lam et al., 2014; Madhav et al., 2009).  
 Most ARVs that are formulated for oral administration are influenced by 
food content in the GIT and the timing of food ingestion. This poses 
certain challenges in children especially in paediatrics that require 
frequent feeding. The buccal route of delivery will not be affected by food 
timing as compared to oral. Hence buccal delivery of drugs will be 
applicable in most patient populations, particularly the paediatrics and 
geriatrics. 
 
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor used as a 
second line ARV regimen in both adult and paediatric population (Schulenburg 
and Le Roux, 2008). The pharmacological and physicochemical properties of 
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ddI makes it a suitable candidate for buccal delivery. The oral bioavailability of 
ddI is as low as 30 % to 40 % which may further be reduced in the presence of 
a meal, and its half-life is 1.3 to 1.6 hours (Bettini et al., 2010; Li and Chan, 
1999).  Additionally, the molecular weight is 236.3 Dalton, its pKa in water is 
9.12 and Log P has been reported as being -1.24 (Moffat et al., 2004). The 
challenges with the current oral use of ddI, in addition to the above properties, 
therefore necessitates that alternative route be explored, and that ddI can be 
considered as a model ARV drug for buccal delivery. The small molecular 
weight will ensure that the drug can diffuse across the cell membranes with 
less difficulty. Furthermore, at the physiological pH of the buccal mucosa of 6 
to 7, ddI will remain mostly in its unionized form which will ensure its interaction 
with the lipoidal cell membrane and improved absorption.  
 
Didanosine has a logP value of -1.24 (Moffat et al., 2004), hence classified as 
a hydrophilic drug and this property may limit its permeability across the lipoidal 
cell membrane. Also, ddI is classified as BCS Class III drug, exhibiting poor/low 
permeability. Moreover, the buccal permeability of drugs is limited by the 
epithelium lining the buccal mucosa. This suggests that the inclusion of a safe 
and effective buccal permeation enhancer will therefore promote the delivery 
of ARVs such as ddI for improved therapy. 
 
At the time of this study, only one other ARV, namely ddC, was investigated 
and reported for buccal delivery (Shojaei et al., 1999; Xiang et al., 2002). The 
buccal delivery potential of ddC was investigated by these two researchers, 
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and they employed bile salts (Xiang et al., 2002), and menthol (Shojaei et al., 
1999) as permeation enhancers.  To the best of our knowledge, these two 
reports on ddC were the only ones found on buccal delivery of ARVs in the 
literature until the studies on ddI, and AVgel as permeation enhancer were 
reported in this study.   Therefore, the potential of the buccal mucosa route for 
delivering ARVs, such as ddI, and carefully selecting permeation enhancers 
needed to be explored. 
 
Recently, studies have reported on permeation potential of other ARVs, i.e. 
tenofovir (TFV) and saquinavir (SQV) (Rambharose et al., 2014a; Rambharose 
et al., 2014b).The incorporation of zidovudine (AZT) into buccal mucoadhesive 
patches (Reddy et al., 2012) and ddI into buccal polymeric films (Jones et al., 
2013) as well as nano-enabled films (Jones et al., 2014; Jones et al., 2013) 
have also been recently reported. 
 
Studies on the buccal mucosa route are ongoing in anticipation of contributing 
to an improved ARV therapy. Buccal delivery of drugs are still attractive to 
scientists across the pharmaceutical industries and in academia. The 
identification of safe and effective permeation enhancers that will contribute to 
the development of buccal delivery systems also continues to attract 
researchers across the globe, until such a time that dosage forms for buccal 






No studies were reported on the buccal delivery potential of ddI, and none on 
the potential of AV gel and OA synthetic derivatives as buccal permeation 
enhancers, particularly using ddI as a model ARV drug. Therefore, the aim of 
the studies reported in this thesis was to explore the potential of the buccal 
mucosa route to deliver an ARV drug, and to identify novel buccal permeation 
enhancers in order to contribute to developing and optimizing novel buccal 
delivery systems that will be useful to improve ARV therapy. 
 
1.3 AIM AND OBJECTIVES 
In order to explore the potential of the buccal mucosal route for the delivery of 
an ARV drug, the sub-Aims and their respective objectives of the study were: 
 
Aim 1.  
To investigate the potential of the buccal mucosal route for delivery of an ARV 
drug using ddI as a model drug. 
 
Objectives: 
1. Determine the permeability parameters of ddI across the buccal 
mucosa  







Aim 2.  
To determine the effects of different novel enhancers such as AV gel, oleic acid 
and the chemically synthesized oleodendrimer derivatives on the buccal 
permeability of ddI. 
 
Objectives:  
3. Investigate the buccal enhancement potential of novel enhancer from 
natural origin, AV Gel by identifying the permeability parameters of 
ddIin the absence and presence of AV gel. 
4. Determine the concentration effects of AV Gel on the buccal 
permeability of ddI. 
5. Investigate the buccal enhancement potential of OA and its 
chemically synthesized oleodendrimer derivatives by identifying the 
permeability parameters of ddI in the absence and presence of 
chemically synthesized novel OA derivatives. 
6. Identify the OA derivative with the best buccal permeation 
enhancement and determine its concentration effects on the 
permeability properties of ddI. 
 
Aim 3.  
To assess the histo-morphological effects of both ddI and the novel enhancers, 






7. To assess the morphological effects of ddI, and the concentrations of 
AV gel and the selected OA derivative as novel permeation 
enhancers on the buccal mucosa. 
8. To evaluate the ultrastructure of the buccal mucosa in order to 
determine the safe concentrations of the novel buccal permeation 
enhancers. 
 
It should be noted that the original protocol for this study included an objective 
for formulation studies, i.e. to incorporate a selected ARV into a novel buccal 
drug delivery system such as monolayered multipolymeric films (MMFs) for the 
buccal route. This objective was indeed addressed in this study and preliminary 
film formulation experiments of MMFs were performed. The preliminary 
experimental findings of this objective have been published as research 
abstracts in ISI journals, i.e. Journal of Pharmacy and Pharmacology, Impact 
factor = 2.006. This published abstract is listed on Pages x – xi, and has been 
included in Appendix VI on page 274. The experimental findings have also 
been presented at both local and international conferences, and the 
presentations have been included in Appendix VII, pages 279 – 285.  These 
preliminary experimental findings were not explored further and are not 
presented as a chapter in this thesis, as the thesis met the current UKZN 
criteria of three (3) publications in the same topic area for an award of a PhD 




1.4 IMPORTANCE OF THE STUDY 
The experimental findings of this study will be of significant benefits in that an 
alternate buccal route for the delivery of ARV drugs, such as ddI, could be 
identified. The identification of alternative route, such as the buccal mucosal 
route, could offer a superior approach over the current oral route of drug 
administration for HIV and AIDS therapy. This could be particularly useful for 
patients for improving compliance and providing better therapeutic outcomes 
of ARV drugs. 
 
The findings could also be significant in widening the pool of buccal permeation 
enhancers for the delivery of ARVs. The buccal permeability of ddI was 
enhanced successfully using products from both natural origin (AVgel) as well 
as chemically synthesized OA derivatives. This means that more sources of 
buccal permeation enhancers could be available, which will broaden the 
categories of permeation enhancers that are suitable in the formulation and 
optimization of buccal drug delivery systems containing ddI. The novel AVgel 
and OA derivatives as buccal permeation enhancers could be applicable to a 
wide range of ARVs as well as other classes of drugs. 
 
The experimental findings of this study could significantly create new 
knowledge in terms of identifying the buccal delivery potential and mechanism 
of buccal permeation of an ARV drug. The mechanism of action of the novel 
buccal permeation enhancers, i.e. AV gel and OA derivatives will create new 
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knowledge in the field of pharmaceutical sciences, and particularly useful for 
the formulation scientists, and for research and development in buccal delivery 
of ARV drugs. The new knowledge created in this study will be a great 
manufacturing resource for the pharmaceutical industries. 
 
Moreover, the enhancers used in this study are synthetic derivatives and 
natural products. They would be of benefit to formulation scientists in that 
different classes of permeation enhancers will be available for selection in the 
formulation, optimization and eventual manufacture and commercialization of 
buccal delivery systems containing ddI, or any other ARVs, and could be 
applicable to other various classes of drugs. 
 
1.5 NOVELTY OF THE STUDY 
At the time of this study, and to the best of our knowledge, only one other ARV, 
in particular, zalcitabine (ddC), was reported for buccal delivery. For the first 
time in the area of buccal delivery research investigating antiretroviral drugs, 
this study identified the buccal delivery potential of ddI, and a possible 
mechanism of ddI permeation across the buccal mucosa was predicted. 
 
AVgel was previously identified as a permeation enhancer for both intestinal 
and skin permeation. This is the first time that AVgel was identified as a buccal 
permeation enhancer particularly for an antiretroviral drug, ddI and for any 
other drug for that matter. The effective and safe concentration of AVgel as 
buccal permeation enhancer for ddI was also identified in this study. The 
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histomorphological evaluations reported in the previous studies on the buccal 
permeability of ddC were limited to the use of light microscopy (LM).This is the 
first time we show that histomorphological evaluations, using both LM and 
transmission electron microscopy (TEM), can be used to access the effects of 
ddI and enhancers on the buccal mucosa. Particularly, the analysis of the 
buccal mucosa using TEM was reported for the first time in buccal delivery of 
ARV. This study shows that the buccal permeation enhancing properties of 
AVgel can be correlated with its effects on the buccal mucosa. 
 
While fatty acids have been reported as chemical permeation enhancers for 
other drugs, the derivatives of fatty acids OA have not been indicated for buccal 
delivery. This is the first time that fatty acids and derivatives, i.e. OA and its 
oleodendrimer derivatives, were used as buccal permeation enhancers for an 
antiretroviral drug, ddI. Identifying the best derivative, as well as its effective 
and safe concentration is reported for the first time. These novel enhancers 
can widen the pool of buccal enhancers for the formulation scientists to explore 
in the development of buccal drug delivery systems, especially for ARVs. This 
new knowledge is particularly desirable, as to date, no specific ARV drug has 
been developed as buccal drug delivery system for commercialization.  
 
This study also identified the most suitable derivative of OA (OANa1A), and 
reported its safe and effective concentration as revealed by TEM analysis and 
proposed its use as buccal enhancer for formulation and optimization of novel 




1.6 THESIS OVERVIEW 
This thesis is divided into the following five chapters:  
 
Chapter 1. Introduction - This chapter outlines the background to the study, 
which included buccal delivery of drugs, permeation enhancement 
strategies and the challenges of current ARV therapy. The buccal 
mucosa route as alternate routes to others such as oral and parenteral 
as well as the advantages and disadvantages of buccal delivery are 
described. This chapter also described AV gel as permeation enhancer 
from natural products origin as well as fatty acids derivatives as synthetic 
chemical permeation enhancers. The potential of the buccal mucosa for 
delivery of ARV drugs was highlighted and the aims and objectives are 
presented in the chapter. 
 
Chapter 2. Publication one - Literature Review – This chapter presents the 
literature which was reviewed and then published as a review article in 
an international ISI journal. The publication’s authors are Elizabeth 
Ojewole, Irene Mackraj, Panjasaram Naidoo and Thirumala Govender 
Other details are: Exploring the use of novel drug delivery systems for 
antiretroviral drugs. European Journal of Pharmaceutics and 
Biopharmaceutics 2008; 70: 697–710 (Impact Factor = 4.245).  The 
Citation counts are reported as follows: Google Scholar = 76, Web of 
Science = 48, and BIOSIS = 31.This publication is a first-authored paper 
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published from the literature reviewed during this study. The review 
article describes several drug delivery systems that were developed for 
ARVs, including buccal, rectal and transdermal drug delivery systems. 
It highlights the significant potential that novel drug delivery systems 
have for the future of ARV drug therapy. This chapter presents the 
literature review in the final revised and accepted version and the format 
required for publication by the journal.  
 
Chapter 3. Publication two - This chapter presents an original research from 
the data generated in this study which was published in an international 
ISI journal. The publication’s authors are Elizabeth Ojewole, Irene 
Mackraj, Kamil Akhundov Josias Hamman, Alvaro Viljoen, Eugene Olivier 
James Wesley-Smith and Thirumala Govender. Other details are: 
Investigating the effect of Aloe vera gel on the buccal permeability of 
didanosine. Planta Medica 2012; 78(4): 354-361 (Impact Factor = 2.339). 
The Citation counts are reported as follows: Google Scholar = 8, Web of 
Science = 6, and BIOSIS = 2). This publication is a first-authored paper 
that reported the experimental findings on the potential of the buccal 
mucosal route for delivery of didanosine. It also highlights the significant 
findings that no adverse effects were observed with ddI and AVgel at their 
selected concentrations. This chapter presents the research paper in the 
final revised and accepted version and the format required for publication 




Chapter 4. Publication three - This chapter presents an original research from 
the data generated in this study which was published in an international 
ISI journal. The publication’s authors are Elizabeth Ojewole, R. 
Kalhapure, K Akamanchi, and T. Govender. Other details are: Novel Oleic 
acid derivatives enhance buccal permeation of didanosine.  Drug 
Development and Industrial Pharmacy 2014; 40(5): 657-668 (Impact 
Factor = 2.006). The citation counts are reported as follows: Google 
Scholar = 1, Web of Science = 0, and BIOSIS = 0. This publication is a 
first-authored paper that reported the potential of oleic acid and its 
oleodendrimer derivatives as buccal permeation enhancers for ddI. This 
chapter presents the research paper in the final revised and accepted 
version, and in the format required for publication by the journal. 
 
Chapter 5. Conclusion. This chapter describes the general conclusions drawn 
from the experimental findings in this study, identifies possible study 
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CHAPTER TWO  
 
LITERATURE REVIEW - PUBLISHED PAPER  
 
2.1 INTRODUCTION 
The following paper was published in an international peer reviewed ISI journal 
and reports the literature review generated during this study. 
 
Elizabeth Ojewole, Irene Mackraj, Panjasaram Naidoo and Thirumala 
Govender. Exploring the use of novel drug delivery systems for antiretroviral 
drugs.  European Journal of Pharmaceutics and Biopharmaceutics 2008; 
70 697–710. 
 
E. Ojewole contributed to the overall content design of this review paper. She 
performed the literature search and identified the relevant articles used in the 
writing of the manuscript. She wrote the initial outline of the topics for the review 
paper. She was responsible for writing the sections on buccal, transdermal and 
rectal delivery. She contributed to writing all the sections in collaboration with 
I. Mackraj, P. Naidoo and the supervisor (T. Govender). Furthermore, she 
contributed to the final draft of the manuscript and revised all the sections 




This chapter is presented in the required format by the ISI journal and is in the 
final revised and accepted version, published in the European Journal of 
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BIOSIS citation Index, accessed 02/11/2014.  
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Novel drug delivery systems present an opportunity for formulation scientists 
to overcome the many challenges associated with antiretroviral (ARV) drug 
therapy, thereby improving the management of patients with HIV/AIDS. This 
paper provides a comprehensive review of the various ARV delivery systems 
that have been developed for achieving sustained drug release kinetics, 
specifically targeting drugs to the macrophages, brain and gastric mucosa, and 
for addressing formulation difficulties such as poor solubility, stability and drug 
entrapment. Studies on the potential of systems for alternative routes of ARV 
drug administration, i.e., transdermal, buccal and rectal are also highlighted. 
The physico-chemical properties and the in vitro/in vivo performances of 
various systems such as sustained release tablets, ceramic implants, 
nanoparticles, nanocontainers, liposomes, emulsomes, aspasomes, 
microemulsions, nanopowders and PheroidTM are summarised. Further studies 
that remain to be undertaken for formulation optimisation are also identified. 
This review highlights the significant potential that novel drug delivery systems 










1. Introduction to HIV/AIDS 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune 
Deficiency Syndrome (AIDS), commonly referred to as HIV/AIDS, constitute 
one of the most serious infectious disease challenges to public health globally, 
and has had a crippling effect in certain parts of the world especially Sub-
Saharan Africa [1-3]. There are currently 33.2 million people living with 
HIV/AIDS globally. Of this total number, an overwhelming 22.5 million people 
are HIV positive in Sub-Saharan Africa specifically, representing 67.8% of the 
global number [3]. Interventions such as AIDS counselling, educational tools 
and antiretroviral drug therapy have contributed to transforming HIV infection 
from a fatal to a manageable chronic infectious disease [4]. Despite the 
availability of these measures, the above statistics indicate that much remains 
to be accomplished as the number of newly reported HIV infections still remains 
unacceptably high. 
 
There are currently two known species of HIV, viz., HIV-1 and HIV-2, with their 
respective subspecies. HIV-1 is the globally common infection while HIV-2 is 
more prevalent in West Africa, and takes a longer time to develop into 
immunodeficiency from infection than HIV-1 [5, 6]. HIV infection in the human 
body results mainly from integration of the viral genome into the host cell for 
the purpose of cell replication, and AIDS is the advanced stage of the disease 
caused by HIV infection. The virus infects the host cell by binding of the viral 
gp120 protein to two transmembrane receptors, i.e., CD4+  and either of  the 
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two chemokine receptors, CCR5 and CXCR4 [7]. HIV infects macrophages and 
T-helper lymphocytes (CD4+); but the defining feature of AIDS is the depletion 
of CD4+ cells. T-tropic viruses prefer to replicate in T cells while M-tropic 
viruses prefer the macrophage. Of the HIV-1 viruses, M tropic types 
predominate in the brain [8]. 
 
The viral genome contains 3 structural genes – gag, pol and env and six 
regulatory genes –tat, rev, nef, vif, vpr, and vpu [5].  The virus utilizes some of 
these genes to maximize its production using host cell resources. DNA 
microarray studies have implicated HIV encoded Nef protein in this process [9], 
and humans infected with the nef-deleted form of HIV have remained disease 
free for several years [10]. Interestingly, HIV has been referred to as a “master 
regulator” of cellular gene expression [9] as a means to augment expression of 
its own genome. An understanding of these processes is critical to developing 
novel therapeutic strategies for the suppression or elimination of the virus. 
 
The immunopathogenesis of HIV/AIDS has been previously amply 
documented; from the time of infection to the end stage of the disease [5].  The 
end stage of the disease may be characterised by a spectrum of diseases [11] 
including opportunistic infections (such as Pnuemocystis carinii and 
Mycobacteruim tuberculosis), dementia and cancer [6, 11]. In addition to 
macrophages, lymph nodes, bone marrow, spleen and lungs, the CNS 
represents one of the most important anatomical sites of the virus after 
infection. This causes significant neuronal damage and loss that often leads to 
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HIV associated dementia [12]. Without treatment, HIV 1 infection is nearly 
uniformly fatal within 5-10 years [11].  
 
2. HIV/AIDS Drug Therapy and its Current Limitations  
Although the development of drugs for HIV infection has undergone substantial 
progress, numerous uncertainties persist about the best way to manage this 
disease. Reports addressing this aspect have appeared in the literature [13]. 
At present, the different ARVs are classified under categories such  as 
nucleoside reverse transcriptase inhibitors (NRTI), nucleotide reverse 
transcriptase inhibitors (NtRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), protease inhibitors (PI), and more recently fusion and integrase 
inhibitors [14]. Table 1 [15-19] lists the various drugs under the different 
classes, the available dosage forms as well as their half-lives and 
bioavailabilities. These drugs are administered as combined therapy as in the 
case of Highly Active Antiretroviral Therapy (HAART) [20].  Among the newer 
classes of drugs under investigation are the assembly and budding inhibitors 
[21], as well as the zinc finger inhibitors [22]. Virus assembly and disassembly 
are particularly attractive candidate processes for antiviral intervention. HIV-1 
capsid (CA) protein and human cyclophilin A (CypA) play important roles in 







Table 1:  Examples of antiretroviral drugs, their commercially available 
dosage forms, bioavailabilities and half-lives. 
 








Zidovudine(NRTI) Capsule, Liquid 60 1.1 
Lamivudine(NRTI) Tablet, Liquid 86 3-6 
Didanosine (NRTI) Tablet, Capsule (EC), 
Liquid 
30-40 1.3-1.6 
Zalcitabine(NRTI) Tablet 85 1-3 
Stavudine(NRTI) Capsule, Powder  for 
reconstitution  
80 1-1.6 
Abacavir(NRTI) Tablet, Liquid 83-100 1-2 
Emtricitabine(NRTI) Capsule 93 10 
Tenofovir NtRTI Tablet 25-39 17 
Nevirapine 
(NNRTI) 
Tablet, Syrup >90 25-30 
Efavirenz(NNRTI) Tablet, Capsule, 
Solution 
42-80 40-50 
Delavirdine(NNRTI) Tablet 85 5.8 
Etravirine (NNRTI) Tablet unknown 30-40 
Amprenavir(PI) Capsule, Solution No data.  7-10 
Indinivir(PI) Capsule 65 1.2-2 
Saquinavir(PI) Tablet, Capsule Erratic, 4 1.5-2 
Nelfinavir(PI) Tablet, Powder 20-80 3.5-5 
Ritonavir (PI) Tablet, Capsule, Liquid 65 3-5 
Atazanavir(PI) Capsule No data 7 
Darunavir(PI) Tablet 37 15 
Enfuvirtide  
(Entry and FI ) 




(Entry and FI ) 
Tablet 23-33 14-18 
Raltegravir (II) Tablet No data 9 
 
NRTI=Nucleoside Reverse Transcriptase Inhibitors 
NtRTI=Nucleotide Reverse Transcriptase Inhibitors  









Although ARV drug therapy has contributed significantly to improved 
patient/disease management, its current use is associated with several 
disadvantages and inconveniences to the HIV/AIDS patient. Many ARV drugs 
undergo extensive first pass metabolism and gastrointestinal degradation 
leading to low and erratic bioavailability. The half-life for several ARV drugs is 
short, which then requires frequent administration of doses leading to 
decreased patient compliance [24].  A major limitation is that HIV is localised 
in certain inaccessible compartments of the body such as the CNS, the 
lymphatic system and within the macrophages. These sites cannot be 
accessed by the majority of drugs in the therapeutic concentrations required; 
and the drugs also cannot be maintained for the necessary duration at the site 
of HIV localization [25]. These sub therapeutic drug concentrations and short 
residence time at the required sites of action contribute significantly to both the 
failure of eliminating HIV from these reservoirs, as well as the development of 
multidrug-resistance against the ARVs [26]. The severe side effects associated 
with ARV therapy can therefore be attributed to the subsequent large doses 
essential for achieving a therapeutic effect, due to the inadequate drug 
concentrations at the site of action, and/or the poor bioavailability of several 
ARV drugs. These drugs also suffer from physico-chemical problems such as 
poor solubility that may lead to formulation difficulties [27, 28].  Strategies 
currently being investigated to overcome these limitations include; the 
identification of new and chemical modification of existing chemical entities, the 
examination of various dosing regimens, as well as the design and 
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development of novel drug delivery systems (NDDS) that can improve the 
efficacy of both existing and new ARV drugs.  More specifically, in the past 
decade there has been an explosion of interest in the development of NDDS 
for the incorporation of ARV drugs as a way of circumventing the problems 
described above and optimising the treatment of HIV/AIDS patients. To the 
best of our knowledge, the last review paper on NDDS for ARV drugs appeared 
in 1993 [28]. There have since been significant advancements of the systems 
described in that paper and further new NDDS for ARV drugs have since 
emerged in the literature. The purpose of this paper is therefore to present a 
comprehensive review of the various NDDS, including studies on alternative 
routes of administration that have emerged for ARV drugs. This will identify the 
progress that has been achieved both for the technological development of 
these delivery systems, as well as their clinical potential for overcoming the 
limitations associated with current ARV therapy. This review will also enable 
the identification of future studies that remain to be undertaken for its 
optimisation and ultimately its commercialisation.   
 
3. Novel Drug Delivery Systems for ARV Drugs  
3.1 Sustained Release/Bioadhesive/Enteric Coated Matrix Tablets 
Sustained drug delivery systems are designed to achieve a continuous delivery 
of drugs at predictable and reproducible kinetics over an extended period of 
time in the circulation. The potential advantages of this concept include: 
minimisation of drug related side effects due to controlled therapeutic blood 
levels instead of oscillating blood levels, improved patient compliance due to 
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reduced frequency of dosing and a reduction of the total dose of drug 
administered [29, 30]. Bioadhesive drug delivery systems are designed for 
prolonged retention on the mucosa to facilitate drug absorption over a 
prolonged period of time by interacting with mucin [31]. Hence, the combination 
of both sustained release and bioadhesive properties in a delivery system 
would further enhance therapeutic efficacy. ARVs such as didanosine (ddI) 
would be an ideal candidate for sustained drug release due to its short half life 
of 1.3-1.6 hours, necessitating frequent administration of doses, as well as its 
severe dose dependent side effects [24]. In an attempt to improve the oral 
absorption of ddI by delivering it over a prolonged period of time as well as 
prolonging retention on the mucosae, Betageri et al. [32] prepared a sustained 
release bioadhesive tablet formulation of ddI, containing Polyox WSRN-303, 
Carbopol 974P-NF and Methocel K4M as polymeric matrix materials. Hydrogel 
forming tablet formulations with 10% and 30% Polyox WSRN-303 were able to 
extend the release of ddI (Figure 1) while 30% Methocel K4M was required for 
extending the drug release in other formulations. Preparations with Carbopol 
934P prevented complete release of ddI from the tablet during the test period 
and the authors attributed this to drug-polymer interactions. The bioadhesivity 
also increased with an increase in polymer concentration. These researchers 
concluded that a single polymer could be used for the preparation of hydrogel 
matrix ddI tablets designed to provide both sustained release and 
bioadhesivity. However, while a single polymer may provide both bioadhesivity 
and sustained drug release, it has since become well recognised in the 
literature, via various in vitro drug release and bioadhesivity tests during 
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formulation studies, that simultaneous optimisation of both these properties 
may require the blending of various polymers [33-35] for both single and 




Figure 1: Effect of Polyox WSRN-303 on the release of ddI from tablets 
(Reproduced from Betageri et al., 2001). 
 
ddI controlled release matrix tablets containing methacrylic (Eudragit RSPM) 
and ethylcellulose (Ethocel 100) polymers have also been prepared by 
Sanchez-Lafuente et al. [36]. The ddI 500 mg tablets (5, 10 or 15 %w/w)  were 
prepared by direct compression and comprised of  Eudragit RSPM and 
Ethocel 100 in varying ratios (75/25, 50/50 and 25/75 w/w). The physical 
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characteristics in terms of weight, thickness and diameter confirmed the 
excellent compactibility properties of these polymers with ddI, which allowed 
for direct compression in the absence of other excipients. The drug release 
studies showed that varying polymer ratios could modulate the release of ddI 
as a result of the swelling properties of Eudragit RSPM and plastic properties 
of the hydrophobic Ethocel 100. Since these two polymers showed potential 
for modulating drug release, the subsequent study by this group focused on 
the use of a statistical experimental design for formulation optimisation as well 
as for identifying and quantifying the effects of formulation variables on drug 
release. Therefore, a Doehlert design was applied to evaluate the influence of 
variables and possible interactions among such variables on ddI release from 
the directly compressed matrix tablets based on the blends of the two insoluble 
polymers, Eudragit RSPM and Ethocel 100 [37]. The drug content and the 
polymers had the most significant effect on drug release while the compression 
force had no significant effect. The optimum formulation conditions identified in 
the studied experimental design for a formulation with optimum drug release 
was Eudragit-Ethocel ratio of 83/17 (w/w) and a drug content of 13 %w/w. The 
experimental values obtained from the optimised formulation highly agreed 
with the predicted values, thereby validating the mathematical model used in 
the preparation of ddI tablets. 
 
ddI also undergoes acid degradation in the gastric medium [38]. An enteric 
coated matrix tablet formulation that combines sustained drug release, 
bioadhesivity and an enteric coating to resist acid degradation to maximise 
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therapeutic efficacy has also been reported. Deshmukh et al. [39] reported the 
preparation of enteric coated, sustained release bioadhesive matrix tablets of 
ddI comprising of Polyox, WSRN-303 and Methocel K4M with 
hydroxypropylmethylcellulose phthalate (HPMCP 5.5). The formulation was 
shown to be resistant to dissolution in 0.1N HCl but dissolved within 10 minutes 
in PBS pH 7.4. Furthermore, the stability of the formulation for 6 months at 
varying storage conditions was confirmed. Permeation studies on the matrix 
tablets showed that Polyox WSRN-303 containing tablets demonstrated higher 
ddI permeability across live intestinal tissue compared with conventional 
tablets. 
 
While the above tablets sought to provide sustained drug release, bioadhesion 
and resistance to gastric acid degradation, a possible limitation could be the 
fact that it would still undergo extensive first pass degradation since it is meant 
for oral administration. 
 
3.2 Ceramic Implants  
Attempts have been made in the literature to explore the use of ceramic 
implants to modulate the release of antiretroviral drugs. Due to the adverse 
effects of AZT associated with oral and intravenous administration, Benghuzzi 
et al. [40] in early in vivo studies investigated the release of deoxynucleoside 
thymidine, the normal counterpart of azidothymidine (AZT), by means of 
alumino-calcium-phosphorous oxide (ALCAP) ceramic implantable capsules in 
rats. The results showed that thymidine could be released from the ALCAP 
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ceramic capsules in a sustained manner for a minimum duration of 120 days. 
Based on the results with thymidine, they subsequently concluded that these 
implantable capsules could be considered for the delivery of AZT. 
Consequently, in a follow up study [41], AZT was loaded into tricalcium 
phosphate (TCP) and ALCAP ceramic capsules. They showed that the rate of 
release of AZT from TCP capsules were lower than from ALCAP capsules.  
Figure 2 confirms the sustained release of AZT from TCP ceramic capsules 




Figure 2: Release of AZT from TCP ceramic capsules (Reproduced from 




To further control release, Nagy and Bajpai [42] extended this in vitro study by 
preparing a TCP ceramic delivery system containing thymidine and AZT and 
determining the effect of sesame seed oil or wheat germ oil on their release. 
Ceramic capsules were prepared by pressing 1 gram of <38 microns beta-TCP 
particles with or without the stipulated quantity of thymidine or AZT in a 10 mm 
die at  a load of 4000 lbs in an electric hydraulic press. They found that sesame 
seed oil and wheat germ oil (Vitamin E) could delay the release of thymdine 
and AZT from TCP drug loaded capsules. Further, incorporation of thymidine 
or AZT in the form of a compressed pellet also retarded its release from the 
TCP ceramic capsules prepared with oil treated ceramic particles. The above 
studies were extended to an in vivo study later [43]. Three ceramic devices 
were implanted subcutaneously in Sprague Dawley rats for two weeks. The in 
vivo studies showed that oil saturated TCP and AZT device as well as the AZT 
pellet inserted in an oil saturated TCP shell device were able to retard AZT 
release at a  significantly lower rate than the AZT and TCP untreated devices. 
These authors concluded that the treatment of ceramic devices with oil 
decreased the release rate and prolonged the delivery of AZT. The inclusion of 
wheat germ into another ceramic device, hydroxyapatite (HA) composite, was 
also able to deliver AZT for prolonged periods in vitro [44].  
 
A subsequent in vivo study by Benghuzzi [45] compared the release of AZT 
from two commonly studied ceramic implants, i.e., TCP and HA. Sterilised drug 
loaded ceramics containing AZT in three dosages (40, 60 and 90 mg) were 
inserted under the skin of rats using standard surgical techniques. The data 
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from this study showed that AZT release rates from TCP ceramic implants (30 
mg=2.380.23 ng/mL, 60 mg=4.641.03 ng/mL  and 90 mg=11.922.35 ng/mL 
serum AZT) were significantly higher than from HA ceramic implants (30 
mg=0.840.05 ng/mL, 60 mg=2.400.83 ng/mL  and 90 mg=6.411.24 ng/mL 
serum AZT ). The authors concluded that TCP and HA ceramic implants could 
be considered effective for delivering AZT in quantities required for  providing 
physiological responses in vivo. The sustained drug release profiles obtained 
indicated that large fluctuations of AZT concentrations in the blood stream and 
tissues, as with conventional routes of administration, could be eliminated 
using ceramic drug delivery systems.  
 
While ceramic implants were actively studied between 1990 and 2000, there 




Liposomes, ranging in size between 25 nm and several microns, are 
microscopic vesicles that comprise one or more phospholipid bilayers which 
surround an aqueous core. They are prepared from natural or synthetic 
phospholipids and cholesterol and may also additionally include other lipids 
and proteins. The aqueous core facilitates the entrapment of hydrophilic drugs, 
while hydrophobic drugs are bound to or incorporated in the lipid bilayer. When 
administered, liposomes are recognised as being foreign and are immediately 
taken up by cells of the mononuclear phagocytic system (MPS). Since the HIV 
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virus localises in these cells, liposomes therefore represent a suitable drug 
delivery system for targeting ARVs into infected cells; and thus have the 
potential of improving the efficacy of drugs and reducing side effects [46, 47, 
48].  
 
The effect of liposomal encapsulation of AZT in mice was determined in early 
studies [49-50]. Unlike injections of free AZT, liposomal encapsulated AZT 
showed no bone marrow toxicity with normal erythrocyte and leukocyte profiles. 
Also, enhanced localisation in the liver, spleen and lung was found with the 
AZT liposomes. Liposomal encapsulated AZT further reduced haematopoietic 
toxicity and resulted in enhanced antiretroviral activity in mice. Liposomal 
formulations have also been prepared for administration of AZT by the 
transdermal route [51]. The optimised liposomal formulation showed a 
transdermal flux of 98.8±5.8 µg/cm2 across rat skin as compared to 5.72±0.3 
µg /cm2 for the free drug and this should contribute to an improved 
bioavailability. These liposomes for the transdermal route were also able to 
target the RES organs more effectively.  
 
Liposomes containing ddI was initially studied by Harvie et al. [52]. They found 
that the elimination plasma half life of 112 nm and 83 nm liposomal ddI was 46 
and 14 times higher than that of the free drug, respectively. They also reported 
efficient targeting of lymph nodes and macrophage–rich tissue with these 
conventional liposomes. In a subsequent study, they were able to extend 
further the ddI half life in plasma from 3.9 hours for conventional liposomes to 
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14.5 hours by incorporating it into sterically stabilized liposomes.  Following 
intravenous injection, the majority of the sterically stabilised liposomes also 
concentrated in the spleen with a peak level at 24 hours (Figure 3) [53]. 
 
Apart from AZT and ddI, zalcitabine (ddC) has also been investigated for 
encapsulation into liposomes by Makabi-Panzu et al. [54-55]. The ddC loaded 
liposomes were more rapidly taken up by the mouse macrophage cell line than 
the free ddC. They also reported that a high intracellular uptake of ddC was 
facilitated by the anionic nature of liposomes. To be pharmacologically active, 
dideoxynucleosides such as ddC must be phosphorylated into 5’-triphosphates 
by cellular kinases. Since some cell types have a low ability to phosphorylate 
these compounds, administration of the phosphorylated form of the drug would 
be most suitable. However, this would not be feasible as cell membranes are 
impermeable to the phosphorylated form, and phosphatases present in body 
fluids hydrolyse nucleotides into the corresponding nucleosides [56]. To 
overcome this limitation and to obtain site specific delivery, the antiviral effects 
of ddC and ddC-triphosphate(ddC-TP) and liposome encapsulated ddCTP 
(L(ddCTP)) were established and compared in cultured, human monocyte 
macrophages infected with HIV-1 [57]. ddCTP was dephosphorylated before 
entering the cells while L(ddCTP) remained stable over days. These 
preparations were also able to inhibit replication at nanomolar drug levels. Data 
obtained from liposome encapsulated ddCTP in a murine acquired 
immunodeficiency syndrome (MAIDS) model has also showed reduced proviral 




Liposomes have also been explored for the encapsulation and delivery of newly 
synthesised prodrugs. Lalanne et al. [59] synthesized two novel glycerolipidic 
ddI conjugates as prodrugs to avoid hepatic first pass metabolism. Liposomal 
formulations (1160nm) of the prodrugs displayed antiviral activity and showed 
promise as formulations for enhancing drug bioavailability.  Due to the low 
entrapment efficiency and high leakage of AZT from liposomes [48], AZT-
myristate (AZT-M) has been synthesized as a prodrug and investigated for its 
potential for liposomal encapsulation. A high entrapment efficiency of 98% was 
achieved with higher plasma AZT being achieved with the AZT-M liposomes 
as compared to free AZT solution. Higher concentrations of AZT in organs of 
the RES and brain were also found with the liposomal preparation. This study 
could have been enhanced if AZT-M liposome preparations were compared 
not only with free AZT, but also with AZT entrapped liposomes.   Prodrug 
liposomal preparations therefore offer the opportunity of not only more efficient 





Figure 3: Plasma and tissue distribution of ddI ([3H]ddI) (A) and liposomal 
lipids ([14C]DPPC) (B) from sterically stabilized liposome-encapsulated 
ddI after the administration of a single intravenous dose (3 mg of ddI per 
kg) to rats. Values are the means obtained for four to six animals per 
group per time point (Reproduced from Harvie et al., 1996) 
 
In addition to liposomes having PEG chains attached to its surface, for 
increasing  circulation time in vivo  [60, 61], active targeting of HIV infected 
cells can also be obtained by using liposomes that have surface attached 
ligands that specifically promote receptor interaction at the site of targeting [47] 
as well. Using the antibody, H-2-K(k), for Fc-mediated targeting; Betageri and 
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Burrell [62] showed that the lipid composition of ddI-triphosphate liposomes  
influenced conjugation of antibodies and also retention of the encapsulated 
drug.  Sterically stabilised immunoliposomes containing grafted anti-HLA-DR 
antibodies were effective in enhancing the concentrations of indinavir (INV) in 
all tissues leading to a 21-126 fold increased accumulation as compared to the 
unencapsulated drug (Table 2)  [63]. Also, immunoliposomal INV was as 
efficient as the free agent to inhibit HIV-1 replication in cultured cells. Lectin 
receptors, which act as molecular targets for sugar molecules, are found on the 
surface of cells of the mononuclear macrophage system (MPS) and have also 
been included in the strategy to improve site specific drug delivery. Using a 
mannose binding protein, concanavalin A, maximum cellular drug uptake 
occurred when mannosylated liposomes containing stavudine (D4T) were used 
[64].  Other sugar molecules used for liposomal formulations to target cells of 
the MPS include galactosylated D4T and AZT liposomes [65-66]. Together, 
these studies confirmed enhanced targeting to tissues rich in galactose specific 
receptors and confirmed their potential of providing sustained drug release 
characteristics. Slepushkin et al. [67] has also reported that synthetic peptides 
can bind specifically to HIV infected cells. The potential of various ligands for 
active targeting of ARV loaded liposomes have therefore been confirmed and 










Table 2: Area under the curve for free and immunoliposomal indinavir in 
tissues after a single subcutaneous administration in mice (Reproduced 










Cervical lymph nodes 523.2 7.6 68.8 
Brachial lymph nodes 617 4.9 126.0 
Mesenteric lymph 
nodes 
192.8 6.4 30.1 
Iguinal lymph nodes 144.5 4.1 35.2 
Popliteal lymph nodes 134.2 4.5 29.8 
Liver 733.3 35.0 21.0 
Spleen 211.3 5.3 39.9 
Plasma 77.8 2.3 33.8 
 
In addition to targeting liposomes to the phagocytic system, other areas in the 
body have also been of interest. Kompella et al. [68] evaluated the effect of 
neutral liposomes on corneal and conjuctival permeability of ddI. While the 
liposomal formulations were able to encapsulate ddI and permeate through the 
rabbit conjuctivial mucosa, the permeability coefficient, initial flux and tissue 
levels of ddI at the end of the transport study were actually lower in the 
presence of liposomal formulations. These neutral liposomes failed to enhance 




One of the disadvantages of liposomes is poor stability in terms of drug 
retention and poor encapsulation. When assessing the stability of ARVs 
incorporated into liposomes, Betageri [69] found that lipid composition 
influenced encapsulation and retention of ddI-triphosphate (ddITP); and that its 
retention in the DMPC:CHOL liposomes was maximum when stored at 4 C. 
 
A novel liposomal formulation, i.e., “emulsomes” for sustained and targeted 
delivery of AZT to the liver has recently been described by Vyas et al. [25]. 
Emulsomes are a novel lipoidal vesicular system with an internal solid fat core 
surrounded by a phospholipid bilayer.  In addition to demonstrating a retarded 
drug release profile (12-15% after 24 hours), studies in rats showed better 
uptake of the emulsomal formulations by the liver cells. We agree with the 
researchers that this proposed cationic emulsome-based system shows 
excellent potential for intracellular hepatic targeting.   
 
Liposomes have clearly been more extensively investigated for their in vitro 
and in vivo properties than other NDDS for ARV delivery. A greater number of 
drugs and prodrugs have been encapsulated and additional formulation 
optimisation techniques and in vivo evaluations have been undertaken.  These 
studies highlight and underscore the potential benefits of liposomes for 








Drug encapsulated nanoparticles are solid colloidal particles that range from 
10-1000 nm in size [70]. Based on their size and polymeric composition, they 
are able to target drug to specified sites in the body and have also shown 
potential for sustained drug delivery [71]. Nanoparticles have also been 
explored for improving the formulation and efficacy of drugs with 
physicochemical problems such as poor solubility and stability [72]. They are 
being increasingly investigated for targeted delivery of ARVs to HIV infected 
cells and to achieve sustained drug release kinetics. Their encapsulation into 
such systems may provide improved efficacy, decreased drug resistance, a 
reduction in dosage, a decrease in systemic toxicity and side effects, and an 
improvement in patient compliance.  
 
Cells of the mononuclear phagocytic system (MPS), such as the 
monocytes/macrophages (Mo/Mac), act as a reservoir for the HIV virus [73]. 
Therefore, drug treatment of HIV infection should involve targeting drugs to 
these cells in addition to the lymphocytes. Several studies involving ARV 
loaded nanoparticles for targeting to the macrophages have consequently 
emerged. In an early preliminary study, Schafer et al. [74] prepared AZT loaded 
polyalkycyanoacrylate (PACA), polymethylmethacrylate (PMMA) and human 
serum albumin (HSA) nanoparticles. This study confirmed uptake of the 
nanoparticles into macrophages isolated from HIV infected patients. The same 
group also later prepared and confirmed the potential of human serum albumin 
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and poly(hexylcyanoacrylate) nanoparticles loaded with the nucleoside 
analogues, AZT and ddC for the targeting of macrophages. These in vitro 
studies were also undertaken using macrophages isolated from the peripheral 
blood of healthy blood donors and transmission electron microscopy [75]. 
Saquinavir (SQN) and ddC, have also been loaded into 
poly(hexylcyanoacrylate) nanoparticles [76] by emulsion polymerization.  While 
ddC showed no superiority to an aqueous solution of the drug in terms of 
reducing the HIV-1 antigen production, a significantly higher efficacy was 
observed for SQN loaded nanoparticles as compared to its aqueous solution. 
An in vivo study in rats to investigate the oral delivery of AZT bound to 
hexylcyanoacrylate nanoparticles for delivery to the reticuloendothelial cells 
was undertaken by Löbenberg, Araujo, and Kreuter [77].  The area under the 
curve (AUC) of [14C] AZT in the liver was 30% higher when the drug was bound 
to nanoparticles than after administration of the solution. Higher AZT levels 
were also found in the blood and brain when nanoparticles were used as 
compared to the control solution. In an in vivo study a year later using the 
intravenous route instead, they showed that AZT concentrations were up to 18 
times higher in organs of the RES if the drug was bound to nanoparticles as 
compared to unbound AZT [78]. Surface modification of nanoparticulate 
systems with hydrophilic groups such as polyethylene glycol has been shown 
to influence the biodistribution of nanoparticles [79]. Using THP-1 human 
monocyte /macrophage (Mo/Mac) cell line, Shah and Amiji [80] showed that a 
significantly higher percentage of the administered dose of nanoparticles was 
internalized within the cells when SQN was incorporated into poly(ethylene 
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oxide)-modified poly (epsilon-caprolactone) nanoparticles (200 nm). Also, 
intracellular SQN concentrations were significantly higher when administered 
in the surface modified nanoparticles as compared to its aqueous solution. A 
possible limitation of this study is that while aqueous solutions of SQN were 
compared to SQN PEG modified nanoparticles, a comparative study with 
surface unmodified SQN nanoparticles was not performed. This would have 
provided greater insight to the contribution of PEG specifically for ARV delivery. 
Most recently, the uptake of AZT loaded poly(lactic acid)-poly(ethylene glycol) 
nanoparticles by polymorphonuclear leucocytes in vitro was shown to be 
dependant on PEG and its ratio in the polymer [81]. 
 
Since the HIV virus can migrate to, multiply and localise in the CNS causing 
several neurological disorders, targeting of ARV drugs to the brain has become 
a significant goal for drug therapy. The blood brain barrier (BBB) prevents 
access of ARVs to the brain due to the tight endothelial cell junctions of the 
brain capillaries and the presence of efflux transporters on the cell surface [81]. 
Nanoparticulate systems promote drug delivery in the brain, since they may 
gain entry by means of endocytosis/phagocytosis and are also moved away 
from the vicinity of efflux pumps [82, 83]. Kuo [84] therefore loaded D4T into 
polybutylcyanoacrylate (PBCA) and methylmethacrylate-
sulfopropylmethacrylate (MMA-SPM) nanoparticles for brain targeting. Drug 
loading of the nanoparticles (59.5-149.2 nm) was inversely proportional to 
particle size and was also affected by freeze-drying and preservation as it 
influenced particle size.  Similar to other studies [85], they also found pH to be 
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critical, since variation in pH value of the loading medium from pH 7.2 led to a 
reduction in the loading efficiency of D4T. Kuo and Chen [86] then evaluated 
the effects of size of PBCA and MMA-SPM nanoparticles and alcohol on the 
permeability of AZT and lamivudine (3TC) across the BBB using blood brain-
microvascular endothelial cells model (BMEC).  Both loading efficiency and 
permeability of AZT and 3TC decreased with an increase in the particle size of 
the two polymeric carriers. While PBCA nanoparticles increased the BBB 
permeability of AZT and 3TC 8-20 and 10-18 fold respectively, the MMA-SPM 
nanoparticles led to a significant 100% increase in the BBB permeability of both 
drugs. A 4-12% enhancement in the BBB permeability of the two drugs with 
0.5% ethanol was attributed to temporary unfolding of tight junctions among 
BMECs upon treatment with alcohol. In a subsequent paper, these authors 
compared the transport of D4T, delaviridine (DLV) and SQV across the in vitro 
BBB using (PBCA),  (MMA-SPM) and also solid lipid nanoparticles (SLNs) [83]. 
These various polymeric systems investigated enhanced permeability of the 
drugs with higher permeabilities being reported with smaller particle sizes.  In 
their most recent paper, Kuo and Kuo [87] showed that exposure to an 
electromagnetic field (EMF) could further enhance drug permeability across the 
BBB. The potential of SLNs for targeted brain delivery of another ARV, 
atazanavir, has also recently been confirmed [88].  
 
More recently, a novel approach was proposed by Dou et al. [89, 90]. They 
postulated that the mononuclear phagocytes, as the principal reservoir for viral 
dissemination, could also serve as a transporter of antiretroviral drugs 
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themselves, since they are responsible for dissemination of HIV, i.e., 
macrophages can enter into tissues that limit entry of many ARV drugs. In 
these two papers, they describe a macrophage based nanoparticulate system 
as a carrier itself for indinavir (INV). A nanoparticle indinavir (NP-INV) 
formulation was prepared and packaged into bone marrow-derived 
macrophages (BMMs). The effects of this drug carrier on drug distribution and 
disease outcomes were assessed in immune competent and human 
immunodeficiency virus type 1 (HIV-1) infected humanised immune-deficient 
mice [89]. Significant lung, liver and spleen BMMs and drug distribution were 
observed. This initial study also reported reduced numbers of virus infected 
cells in plasma, lymph nodes, spleen, liver and lung as well as CD4(+) T-cell 
protection when the NP-IDV BMMs were administered to HIV-1 challenged 
humanised mice. Later, a similar NP-INV formulation was prepared with Lipoid 
E80 [90]. They reported sustained drug release from the macrophages. The 
administration of NP-INV, when compared to equal drug levels of free soluble 
INV, also significantly blocked induction of multinucleated giant cells, 
production of reverse transcriptase activity in culture fluids and cell associated 
HIV-Ip24 antigens after HIV-1 infection. This study proved that use of a 
macrophage based NP delivery system has potential for the treatment of HIV-







Figure 4: Scanning electron micrograph of ddI loaded mannose coupled 
gelatin nanoparticles (x30000) (Reproduced from Jain et al., 2008). 
 
The use of ligands on nanoparticles for receptor mediated targeting has just 
been reported in the literature [91-92]. Since macrophages contain various 
receptors such as mannosyl, galactosyl and others, Jain et al [91] prepared 
mannosylated gelatine nanoparticles (MN-G-NP) (248-325 nm) (Figure 4) with 
a drug encapsulation  of 40.2-48.5%. Via fluorescence and ex vivo studies 
using alveolar macrophages from rats, they showed a 18.0 and 2.7 times 
higher uptake by the macrophages from MN-G-NPs as compared to the free 






Figure 5: Drug uptake from ddI containing mannosylated gelatin 
nanoparticles by alveolar macrophages at different time points at 372C 
(Reproduced from Jain et al., 2008). 
 
The use of nanoparticles for targeting other areas, such as the gastrointestinal 
mucosa and associated lymphoid tissues has also been reported by Dembri et 
al. [93]. As compared to the drug solution, AZT loaded isohexylcyanoacrylate 
nanoparticles were able to efficiently concentrate AZT in the intestinal mucosa. 
They also found that the nanoparticles were also able to control the release of 
free AZT.   
 
Solid lipid nanoparticles (SLNs) are prepared from lipids that remain in a solid 
state at room and body temperature. Heiati et al. [94] initially prepared SLNs 
consisting of AZT-palmitate (AZT-P) and trilaurin (TL) as the solid core with 
dipalmitoylphosphatidylcholine (DPPC), and a mixture of DPPC and 
dimyristoylphosphatidylglycerol (DMPG). Their study concluded that the 
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loading of AZT-P was proportional to the concentration of phospholipids 
content and was independent of the amount of trilaurin used. Phospholipids 
with transition temperatures below 37C increased drug release. In a 
subsequent study, coating the SLNs with a PEG layer on its surface further 
increased the levels of AZT in the blood, since PEG creates a steric barrier that 
reduces particle uptake, thereby prolonging circulation [95]. They also found 
that the SLN-PEG nanoparticles were able to decrease the drug release rate 
in plasma as compared to SLN particles without PEG. The studies by this 
research group confirmed that surface modification with PEG could be used for 
controlling drug release and the pharmacokinetic behaviour of SLNs. 
 
While the majority of studies have focused on targeted delivery of ARVs with 
nanoparticles, some studies have also focused on modifications to its 
preparation to enhance drug loading and decrease toxicity; and also to 
increase its absorption by facilitating pH-sensitive drug release. Boudad et al. 
[96] prepared SQN loaded poly(alkylcyanoacrylate) nanoparticles and showed 
that incorporation of cyclodextrins enhanced the entrapment of SQN.  Studies 
on the Caco-2 cell line showed that incorporation of cyclodextrins with 
nanoparticles decreased cytotoxicity when compared to blank and SQN loaded 
nanoparticles. The ability of cyclodextrins to mask to some extent the cytotoxic 
effects of the aliphatic alcohols originating from the hydrolytic degradation of 
the polymers was proposed as a possible reason for this effect. The oral 
bioavailability of a poorly water soluble HIV-1 protease inhibitor (CGP 70726-
Novartis) was also enhanced when incorporated into pH sensitive 
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nanoparticles prepared from poly(methacrylic acid-co-ethacrylate) copolymer 
Eudragit L100-55  [72].  
 
The surge of interest in nanoparticulate systems for ARV therapy has led to 
several drugs being studied for its incorporation. These in vitro/in vivo studies 
clearly confirm the ability of nanoparticles to enhance the therapeutic efficacy 
of ARVs, as well as, addressing formulation problems. 
 
3.5 Nanocontainers 
Dendrimer based systems have also been explored for the concept of ARV 
targeting. Dendrimers are characterized as being synthetic, highly branched, 
spherical monodispersed macromolecules. Due to their unique architecture 
and macromolecular characteristics, they have emerged as an important class 
of drug carrier for targeted delivery [97-98]. Hence, not surprisingly, they have 
just been reported for targeting of ARV drugs. Recently, Dutta et al. [99] 
prepared poly(propyleneimine) (PPI) dendrimer based nanocontainers for 
targeting of efavirenz (EFV) to Mo/Mac. Fifth generation PPI dendrimer, t-Boc-
lycine conjugated PPI dendrimer (TPPI) and mannose conjugated dendrimers 
(MPPI) were synthesized and used to prepare “nanocontainers”.  Like a 
dendritic box, these molecules act as closed containers of nanoscopic size 
containing the entrapped drug and are therefore called nanocontainers. The 
drug entrapment efficiency of the nanocontainers varied, with the mannose 
conjugated dendrimer being 47.4%, followed by that of the PPI dendrimer 
(32.15%) and t-Boc-glycine conjugated dendrimer (23.1%). While the PPI 
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dendrimer released the drug by 24 hours, the dendrimer based nanocontainers 
of t-Boc glycine and mannose conjugated dendrimers prolonged the release 
rate up to 144 hours. The authors found significant increase in cellular uptake 
of EFV by Mo/Mac with nanocontainers of the mannose conjugated dendrimer 
being 12 times higher than that of free drug and 5.5 times higher than those of 
t-Boc-glycine conjugated dendrimer. Further, PPI showed a very high toxicity 
on HEPG2 cells while TPPI and MPPI had negligible toxicity (Figure 6). These 
differences were attributed to the free terminal amino groups in PPI which is 
masked in MPPI and TPPI. This study therefore showed that mannosylated 
PPI dendrimers could be an effective carrier system for targeted delivery of 












Figure 6: Cytotoxicity of poly(propyleneimine) (PPI) dendrimer and its 
nanocontainers, t-Boc-lycine conjugated PPI dendrimer (TPPI) and mannose 
conjugated dendrimers (MPPI) (a) after 24 h and (b) after 48 h of incubation for 
targeting of efavirenz (EFV) to Mo/Mac. (values = mean SD, n=3) 
(Reproduced from Dutta et al., 2007). 
 
3.6 Micelles and Microemulsions 
Microemulsions have been studied for ARV drug delivery as an approach to 
redirect the absorption of ARV from the portal blood to the HIV-rich intestinal 
lymphatics, thus enhancing the bioavailability of drugs that undergo extensive 
first-pass metabolism and have poor oral bioavailability. Three formulations of 
SQN containing oleic acid have been studied [100] for targeted intestinal 
lymphatic transport using rats as the in vivo model: cremophor-oleic acid mixed 
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micelles, D-Alpha tocopheryl polyethylene glycol 1000 succinate (TPGS)-oleic 
acid mixed micelles and an oleic acid microemulsion. The extent of lymphatic 
transport from the lipid vehicles was 0.025-0.5% of the dose administered. The 
microemulsion generated higher and more prolonged mesenteric lymph 
concentrations than the micellar formulations (Figure 7). The systemic 
bioavailability was estimated to be 8.5% and 4.8% for the cremophor mixed 
micelle and the microemulsion, respectively. Since the cremophor mixed 
micelles produced higher bioavailability than TPGS mixed micelles, the 
researchers concluded that the nature of the surfactant can influence 
biodistribution of the drug between lymph and plasma. 
 
Figure 7: Concentration of SQN in intestinal lymph versus time (Mean S.E., 
n5). SQN (5 mg) was administered intraduodenally to anaesthetized rats in a 
cremophor-oleic acid mixed micellar formation (closed circle), a TPGS-oleic 
acid mixed micellar formulation (closed circle) or as an oleic acid 






Most recently, nanopowders have been used as a delivery system for oral 
administration to enhance the dissolution rates of poorly soluble drugs.  Tween 
80/poloxamer 188 stabilised nanosuspensions of the hydrophobic ARV, 
loviride, were prepared by media milling, and sucrose co-freeze dried to obtain 
solid nanopowders [101].  Morphological characterisation showed plate like 
structures in the nanopowder which was different from the morphology of 
untreated loviride crystals (Figure 8) Loviride showed higher dissolution rates 
in nanosized products than in their respective physical mixtures, i.e., the 
amount of drug released after 15 minutes was 104.2% for the nanopowder 
prepared from freeze drying with sucrose, 58% for the freeze dried 
nanosuspension without sucrose, 54.8% for the physical mixture containing 
sucrose, 14.5 % for the physical mixture without sucrose and 64.7% for the 
pure untreated loviride (Figure 9). The addition of sucrose also further 
enhanced the dissolution rates. Caco-2 experiments revealed a significantly 
higher transport of loviride from the nanopowder formulation as compared to 
the physical mixture and the untreated loviride. Nanopowders were able to 
increase the dissolution rate due to its high surface area while sucrose had an 























Figure 8:  Scanning electron micrographs of 1) nanopowder and 4) 










Figure 9:  Dissolution profiles: freeze-dried nanosuspension without 
sucrose (open diamond), physical mixture without sucrose (closed 
diamond), nanopowder (Open Square), physical mixture with sucrose 
(closed square), and untreated loviride (closed triangle). (Reproduced 




Since studies with INV in HIV positive patients have indicated that drug 
concentrations in lymph node mononuclear cells were about 25-35% of 
mononuclear cells in blood, in a proof of concept study, Kinman et al. [102] 
showed that association of INV with lipids could enhance localisation in 
lymphoid tissues and also reduce the viral load. This was accomplished by 
preparing lipid associated complexes in suspension for subcutaneous injection 
to HIV-2287-infected macaques. They showed that INV concentrations in both 
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peripheral and visceral lymph nodes were 250-2270% higher than plasma as 
compared with <35% with soluble lipid-free drug administration in humans. 
Also, administration of the INV-lipid complexes reduced significantly the viral 






Figure 10:  Changes in plasma viral load of one HIV-2287-infected 
macaques at 25 weeks postinfection and treated with 10 daily 20-mg/kg 
(SC) doses of lipid-associated indinavir over 14 days. (Reproduced from 
Kinman et al., 2003). 
 
3.9 Transdermal delivery  
The advantages offered by drug administration via the transdermal route 
include; avoidance of first pass effect and/or GI degradation, reduced 
fluctuations in plasma drug concentrations, excellent targeting of the drug for 
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local effect as well as improved patient compliance [103, 104]. The potential of 
ARVs for transdermal administration has therefore been extensively reported. 
The various transdermal permeation studies with ARV drugs specifically in 
terms of the focus/foci of the particular investigation and main outcomes of the 
study are summarised in Table 3. The most commonly investigated drug thus 
far for transdermal delivery has been AZT, although there are some studies 
that have also investigated ddC and ddI for transdermal delivery. One of the 
limitations of transdermal delivery of drugs is poor skin/percutaneous 
penetration/absorption of drugs. Hence, the majority of ARV transdermal 
studies have focused on permeation enhancement investigating, inter alia, 
various chemical enhancers, type of vehicles (solvents/cosolvents), as well as 
iontophoresis and anodal current application. Table 3 identifies specifically the 
various penetration enhancers and vehicles that have been specifically 
investigated thus far. These various permeation enhancement variables either 
alone or in combination have been found to be beneficial in promoting ARV 
drug permeation through the skin.   
 
In addition to comparative permeation enhancement studies with drug 
solutions, some studies have developed and evaluated transdermal delivery 
systems of an ARV drug.  Gels containing AZT [105, 106] and AZT patches 
using a gum matrix [107, 108] have been developed. Both were found to be 
capable of facilitating ARV permeation and the gel formulations were also 
found to be more stable than drug solutions. One of the first vesicular carriers 
to be studied for transdermal delivery of AZT was aspasomes [109]. These are 
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vesicles formed from ascorbyl palmitate (ASP) in combination with cholesterol 
and a negatively charged lipid (dicetyl phosphate). Figure 11 shows that 
aspasomal AZT (ASP-AZT) was able to significantly enhance transdermal 
permeation of drug as compared to the AZT solution. Although lower than ASP-
AZT, the higher drug permeation of  ASP-AZT dispersion as compared to AZT 
free drug solution showed that ascorbyl palmitate had skin permeation 
enhancing properties. An elastic liposomal formulation of AZT has also 
enhanced transdermal flux, provided sustained drug release and improved site 
specificity of the drug [51]. PheroidTM is a patented submicron emulsion which 
has been shown to entrap, transport and deliver several pharmacological 
compounds for enhanced therapeutic action [110, 111]. PheroidTM comprises 
essential and plant fatty acids, i.e., ethyl esters of the essential fatty acids, 
oleic, linolenic and linoleic acids, which are emulsified in water and saturated 
with nitrous oxide. As shown in Table 2, oleic acid is an effective permeation 
enhancer due to its kinked structure that briefly disrupts the packed formation 
of the intercellular lipids [112]. Recently, the use of Pheroid TM was investigated 
for its potential to enhance the transdermal permeation of ddC, 3TC and 
several N-acyl lamivudine esters [113].  However, while the drugs were shown 
to be entrapped in the PheroidTM, the transdermal flux of the drugs in PheroidTM 
was lower than in PBS. Hence, the PheroidTM delivery system showed no 






Figure 11: In vitro permeation profiles of AZT across excised rat skin 
following treatment with various systems i.e. aspasomal AZT 
(ASPASOME); AZT-ASP dispersion (AZT+ASP), free AZT solution (AZT-
Soln) (Reproduced from Gopinath et al., 2004). 
 
The various transdermal delivery studies with drugs such as ddI, ddC and AZT 
using various animal models such as the skin of rat, mouse, pig and human 
cadaver have confirmed the potential of ARV drugs for transdermal delivery.  
 
 
3.10 Buccal delivery  
Delivery of drugs via the buccal mucosa has received increased attention in 
the literature as an attractive alternative to the traditional oral and other 
conventional routes of drug administration.  Use of the buccal mucosal route 
presents several advantages, such as the bypass of first pass hepatic 
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metabolism and avoidance of gastrointestinal enzymatic degradation, thereby 
increasing the bioavailability of drugs [114]; higher permeability than that of the 
other routes such as the skin [115]; larger surface area for drug application, 
and good accessibility compared to other mucosal surfaces such as nasal, 
rectal and vaginal mucosa [116]. ARV drugs may therefore benefit from buccal 
mucosal administration instead of traditional oral administration.  
 
Studies investigating the feasibility of the systemic buccal delivery of anti-HIV 
drugs have emerged. Shojaei et al. [117] initially investigated the use of a safe 
and effective permeation enhancer, i.e., menthol, on the buccal permeation of 
ddC. This study showed that the in vitro transbuccal permeation of ddC 
increased significantly in the presence of 1-menthol with an enhancement 
factor of 2.02 and a tlag of 6 hours. The permeation enhancement was not 
concentration dependent as no significant difference was observed between 
the permeation enhancement of ddC in the presence of 0.1, 0.2, and 0.3 mg/mL 
of 1-menthol [117]. Later, Xiang et al. [27] also studied the feasibility of 
transbuccal delivery of ddC using McIlvaine buffer solution (IMB). Their study 
focused on identifying the major permeation barrier within the epithelium of the 
buccal mucosa, the influence of sodium glycodeoxycholate (GDC) as a 
permeation enhancer as well as the histological effects of ddC on the buccal 
mucosa. These researchers reported that the basal lamina layer within the 
epithelium of buccal mucosa acted as an important barrier to the permeation 
of ddC. They also found that the permeability of ddC was significantly 
enhanced by GDC up to 32 times (Figure 12). Histological studies revealed 
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that the basal lamina remained intact and no nucleated cell leakage was found 
within 24 hours. These studies also showed that the thickness of epithelium 
was greatly reduced after buccal tissues were immersed in IMB solution for 12 
and 24 hours, and no difference was observed between the tissue samples 
incubated in the IMB and ddC IMP solution. These two research groups 
concluded that transbuccal delivery is a potential route of administration of ddC, 





Figure 12: Cumulative amount of ddC permeating through the porcine 
buccal mucosa without GDC (closed triangle) and with co-administration 
of GDC (closed square). Data are presented as meansS.D. (n=3) 







Unlike the transdermal route, the buccal route for ARV permeation potential 
has not been comprehensively investigated. The reported studies to date have 
focused only on 2 different permeation enhancers and no studies on the 




3.11 Rectal delivery  
The rectal route has also been considered for effective delivery of ARV drugs 
that undergo first pass hepatic metabolism and/or extensive GI degradation. 
Two studies were found to have been reported in the literature. Sustained-
release AZT suppositories were prepared [118] using hydroxypropyl cellulose 
(HPC) and assessed in rats. It was found that AZT suppositories at 10 mg/kg 
maintained constant plasma levels above 1 µM for more than 6 hours and they 
subsequently proposed suppositories as an alternative drug delivery system 











Figure 13:  Plasma concentration-time profiles following the administration of 
AZT suppositories: conventional (open triangle) and sustained release (open 
circle) (Reproduced from Kawaguchi et al., 1991). 
 
A further study of rectal administration of AZT [119] showed that the drug was 
considerably absorbed after rectal administration, with a pharmacokinetic 
profile that resembled that of a sustained-release delivery device No further 
studies on this approach have since been identified in the literature. The work 
in this area appears to be limited, most probably due to patient inconvenience, 















Table 3: Summary of transdermal delivery studies on ARVs. 
 
ARV Drugs Focus/Foci of study Summary of main 
findings 
Reference 
AZT Investigated effect of N-methyl-2-
pyrrolidone (MP) as a penetration 
enhancer and ethylene-vinyl acetate 
copolymer membrane for controlled-
release. 
Permeation of AZT was 
significantly enhanced 
and plasma 
concentration of AZT 
maintained for 10 hours 
after the application of 
MP controlled - release 
transdermal system. 
[120] 
ddI Explored transfollicular absorption 
route for ddI and investigated effect 
of penetration enhancers, i.e. azone 
and propylene glycol. Determined the 
pharmacokinetics of ddI after topical 
application. 
Systemic bioavailability 
in high and low follicular 
density rats was similar 
indicating unimportant 
role of the transfollicular 
route for ddI. 
Transdermal delivery of 
ddI exceeded the oral 
bioavailability and was 




AZT Investigated the effect of t-anethole, 
carvacrol, thymol, linalool and L-
menthol. Determined the in vivo 
performance of AZT gel formulation. 
Transport of AZT was 
optimum with 5% 
enhancer 
concentrations. In vitro 
studies produced higher 
amount and rate of AZT 






Determined stability profiles of drugs 
in solution when in contact with 
hairless rat skin and identified the 
degradation mechanisms of ddC and 
ddI. 
AZT was found to be 
stable for 30 hours at 
37oC. ddC and ddI 
degraded by bacterial 
and ddI by cutaneous 
enzyme- degradation 
mechanisms. ddC was 
stabilized with 
thimerosal or 
gentamicin, while ddI 






ddC Investigated the effects of 
ethanol/water and ethanol/tricaprylin 
cosolvents and other permeation 
enhancers such as oleic acid and N-
methyl-2-pyrrolidone. 
Permeation rate across 
human cadaver skin was 
significantly lower than 
across hairless rat skin. 
Enhancement of ddC 
permeation using 1 %v/v 
of oleic acid in 
ethanol/water (60:40) 
cosolvent was 4-5 times 
higher than target rate of 
0.14mg/cm2/h to 
maintain the therapeutic 
blood level. 
[123] 
AZT Determined drug release from AZT 
patches made from Karaya gum 
through excised hairless mouse skin 
and also investigated the effect of 
enhancers. 
Thickness of gum matrix 
and enhancers such as 
propylene glycol, oleic 
acid, and sodium 
dodecyl sulphate 
influenced drug release 
from patches. 









Investigated effects of ethanol/water 
and ethanol/tricaprylin as cosolvent 
systems and oleic acid as 
permeation enhancer on permeation 
rate of each of the drugs alone. 
Permeation rates of 





Addition of oleic acid to 
the ethanol/water 
system enhanced 




rates reached the target 
for  required therapeutic 
levels with ethanol/water 
(60:40) containing oleic 





Investigated effects of ethanol/water 
and ethanol/tricaprylin as cosolvent 
systems and oleic acid as 
permeation enhancer on the 
simultaneous skin permeation of the 
3 drugs together using hairless rat 
skin. 
Permeation rates of 




Addition of oleic acid in 
ethanol/water (80:20) 
significantly increased 










Compared the skin permeation rates 
of ddC, ddI and AZT, alone or in 
combination with various 
compositions of ethanol/water and 
ethanol/tricaprylin cosolvent systems, 
across human cadaver and rat skins. 
Human cadaver skin 
permeation rates of the 
drugs alone, or in 
combination were lower 
than the rat skin. The 
addition of oleic acid at 
0.3 – 1% v/v increased 
permeation rate of all 
three drugs. 
5 % v/v oleic acid 
increased permeation 









Compared permeation rates of 
drugs. Permeation enhancing effects 
of ethanol/water systems and oleic 
acid were investigated. 
Permeation increased 
as volume fraction of 
ethanol increased. For 
ddC, ddI and AZT, 
addition of oleic acid 
(>2.0%w/v) in 
ethanol/water (70:30) 
further enhanced skin 
permeation rate. 
Enhancement for 
hydrophilic drugs was 
greater than for lipophilic 
drugs. 
[127] 
AZT Investigated transdermal flux of AZT 
using iontophoresis and propylene 
glycol/oleic acid. Effect of flux 
enhancement by iontophoresis was 
also investigated using a karaya gum 
matrix formulation of AZT and 
compared with AZT solution. 
Enhancement of 
transdermal flux by 
iontophoresis was 
smaller with the karaya 
gum matrix containing 
AZT. The iontophoretic 
flux from AZT solution 
increased about 4-5 fold. 
Penetration enhancers 
increased the passive 






AZT Investigated permeation of AZT 
using penetration enhancers such 
as: menthol, cineole, linolenic acid, 
oleic acid, in combinations of cineole 
or menthol with either oleic acid or 
linolenic acid or anodal current 
application. 
Permeability enhancing 
properties of the 
penetration enhancers 
were in the order of 
linolenic acid > menthol 
> oleic acid > cineole > 
vehicle.  Combination of 
cineole and oleic acid 
enhanced permeation. 
Simultaneous 
application of current 




AZT Compared permeation of a AZT gel 
formulation including penetration 
enhancers (menthol and oleic acid) 
with solutions. 
Gel formulation was 
found to be more stable 
than solutions. There 
was no retardation in 
permeability of AZT in 
the gel formulation 
across the rat skin 
compared to the AZT 
solution.  Combination of 
penetration enhancers 
at 2.5% w/w enhanced 
permeation. 
[105] 
AZT Investigated effects of binary 
vehicles [ethanol/water; isopropyl 
alcohol/water; polyethylene 
glycol/water; and ethanol/isopropyl 
myristate (IPM)], penetration 
enhancers [N-methyl-2-pyrrolidone 
(NMP); oleic acid; and lauric acid] 
and polymer [microporous 
polyethylene (PE) membrane] on 
permeation. 
Ethanol/IPM (50/50, v/v) 
demonstrated highest 
transdermal flux. Use of 
vehicle and enhancer 
combinations 
(ethanol/IPM 20/80 plus 
10% NMP and 
ethanol/IPM 30/70 plus 
10% NMP) resulted in 
increased AZT solubility 
as well as high AZT flux 
values, when compared 
to vehicles without 
enhancers. 
[129] 
AZT Investigated permeation of AZT 
across human cadaver skin and the 
effect of terpenes [L-menthol and 1, 
8-cineole] on phase behavior and 
molecular organization of a model 
Stratum Corneum (SC) lipid system. 
 
Terpenes enhanced 
permeation of AZT by 
transforming SC lipids 
from a highly ordered 
orthorhombic 
perpendicular 
subcellular packing to a 
less ordered hexagonal 
subcell packing. 
Terpenes caused 
disruption / alteration in 
the barrier property of 
SC and enhanced 
permeation of AZT more 




AZT Evaluated the formation and 
transdermal permeation properties of 
aspasomes containing AZT. 
Proportion of cholesterol 
affected drug release 
rate with maximum 
retardation achieved 
with 45 mol% of 
cholesterol. Aspasomes 
had better antioxidant 
activity than ascorbic 
acid. Asposomal AZT 
enhanced transdermal 
permeation of the drug. 
[115] 
AZT Evaluated use of elastic liposomes 
for transdermal delivery of AZT 
Elastic liposomes 
enhanced transdermal 
flux, provided sustained 
drug release and 







Determined the in vitro transdermal 
permeation of ddC, 3TC and 
synthesized 3TC esters through 
human epidermis with or without 
PheroidTM as drug delivery system 
Drugs with higher 
aqueous solubilities 
displayed greater 
transdermal flux values 
both in PBS and 
PheroidTM .Transdermal 
flux values of drugs in 
PheroidTM were lower 




4. Conclusions and Future Studies 
Despite significant advances that have been made in understanding the 
mechanism of HIV infection and identifying effective treatment approaches, the 
search for optimum treatment strategies for AIDS still remains a major 
challenge. Results presented in this review indicate that novel drug delivery 
systems clearly present an opportunity for formulation scientists to overcome 
the many challenges associated with antiretroviral drug therapy. The use of 
such systems began in the early 1990’s but it is only within the past 5 years 
that there appears to be a sudden surge of interest and publications in the use 
of novel drug delivery systems for ARV drugs. While several novel drug delivery 
systems have been investigated for ARV delivery, recently there appears to be 
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greater interest and advancement in the use of liposomes and nanoparticles 
as compared to other systems. While the clinical potential for several NDDS 
have been reported from in vitro and animal studies, there is a lack of data on 
formulation optimisation and detailed physico-chemical/mechanical 
characterisation of these NDDS. Since HIV/AIDS treatment involves 
combination drug therapy, the potential of these novel drug delivery systems 
for simultaneous loading of various drug combinations needs to be 
investigated. While the potential of alternate routes of ARV drug administration 
such as transdermal and buccal has been confirmed, the design and 
development of drug delivery systems for these routes specifically are currently 
lacking. Correlations between the performances of these systems with their 
permeation potential need to be established. Although various papers report 
efficacy studies under in vitro conditions including experimental animal studies, 
there is a significant lack of data on the clinical applicability (human in vivo 
studies) and toxicity of these preparations. These therefore need to be 
extensively explored.  Based on the complexity of the disease and the 
formulation optimisation and evaluation studies required, multidisciplinary 
research would be essential for eventual commercialisation of NDDS 
containing ARV drugs. 
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The buccal mucosal route offers several advantages but the delivery of certain 
drugs can be limited by low membrane permeability. This study investigated 
the buccal permeability properties of didanosine (ddI) and assessed the 
potential of Aloe vera gel (AVgel) as a novel buccal permeation enhancer.   
Permeation studies were performed using Franz diffusion cells and drug was 
quantified by UV spectroscopy. Histomorphological evaluations were 
undertaken using light and transmission electron microscopy. The permeability 
of ddI was concentration-dependent and it did not have any adverse effects on 
the buccal mucosae. A linear relationship (R2 = 0.9557) between the 
concentrations and flux indicated passive diffusion as the mechanism of drug 
transport. AVgel at concentrations of 0.25 to 2 %w/v enhanced ddI permeability 
with enhancement ratios from 5.09 (0.25 %w/v) to 11.78 (2 %w/v), but 
decreased permeability at 4 and 6 %w/v. Ultrastructural analysis of the buccal 
mucosae treated with PBS, ddI/PBS and ddI/PBS/AVgel 0.5 %w/v showed 
cells with normal plasmalemma, well-developed cristae and nuclei with regular 
nuclear envelopes. However cells from 1, 2 and 6 %w/v AVgel-treated 
mucosae showed irregular nuclear outlines, increased intercellular spacing and 
plasmalemma crenulations. This study demonstrates the potential of AVgel as 
a buccal permeation enhancer for ddI to improve anti-HIV and AIDS therapy. 
KEYWORDS: 
Buccal, Didanosine, Permeation enhancer, Histomorphology, Aloe vera (L.) 






Antiretroviral (ARV) drugs have revolutionized the treatment of HIV (Human 
Immunodeficiency Virus) infection and AIDS (Acquired Immune Deficiency 
Syndrome) [1], widely acknowledged as being among the most serious public 
health problems [2]. However, several limitations exist with current ARV drug 
therapy via the oral route [3, 4]. These drugs suffer from low bioavailability due 
to extensive first pass effects and gastrointestinal degradation. Also, short half-
lives necessitate frequent administration of doses and severe dose dependent 
side-effects may occur.  
 
Buccal drug delivery, which is administration of drug from a delivery system 
(e.g. films, patches and gels) through the mucosae lining the cheeks of the 
mouth, has received increased interest as an alternative to the oral route. 
Drugs administered via the buccal route can bypass enzymatic degradation 
and hepatic first pass metabolism thereby improving bioavailability [5,6]. It has 
a high patient acceptability compared to other non-oral routes [7]. Buccal 
delivery systems offer an attractive approach for pediatrics and for patients with 
swallowing problems.  Buccal delivery of ARV drugs can therefore contribute 
to overcoming some of their current disadvantages. While the potential of ARV 
drugs for administration via another non-oral route namely the transdermal 





The epithelium lining the oral cavity is a barrier to drug permeation. The use of 
permeation enhancers in many cases is essential for efficient buccal drug 
delivery [10, 11]. The discovery of new permeation enhancers is essential for 
optimizing drug delivery via the buccal route. Currently, there is an increasing 
interest for drug products that either are of natural origin or contain such 
components [12]. Aloe vera (Aloe barbadensis Miller) is a succulent plant with 
strap-shaped green leaves [12]. For medicinal applications, the aloe latex (or 
exudate), the aloe gel and the whole leaf (or whole leaf extract) are the main 
parts used [13]. The inner pulp of the fresh leaves is used for gel extrusion [14].  
The gel is composed mainly of water (>99%) and the remaining 0.5-1% of solid 
material comprises several polysaccharides, vitamins, enzymes, lipids and 
inorganic and small organic compounds [15]. It is recognized as an important 
medicinal plant that has effective anti-inflammatory, antifungal, soothing effect 
on the mucosal lining and wound healing properties (16). While it has recently 
been shown to be an effective transdermal [17] and intestinal [13] penetration 
enhancer for various drugs, its applicability for buccal permeation 
enhancement has not been investigated before. In these in vitro permeation 
studies by Chen et al 2009, it was reported that the polysaccharides from Aloe 
vera gel is capable of reducing the TEER of excised rat intestinal tissue, thus 
enhancing the transport of atenolol across this tissue to a significant extent. 
Moreover, Aloe vera gel materials could significantly decrease the TEER of 
Caco-2 cell monolayers and this reduction in TEER was associated with the 
opening of tight junctions between adjacent epithelial cells and this effect was 
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completely reversible after removal of the Aloe vera leaf materials from the cell 
monolayers.  (Chen et al 2009). 
Cole and Heard (2007) also stated that the skin penetration enhancement 
effect of AVgel was due to a probable pull effect of complexes formed between 
the compound and the enhancing agent within the aloe gel, however, the 
proposed mechanism of action has to be further investigated and confirmed as 
stated by the authors. Those studies with AVgel as an enhancer for the 
intestinal and transdermal routes did not report its histomorphological effects 
[13, 17], which is important for assessing its preliminary suitability. Recently, it 
has been shown to have the potential to modify drug release profiles in dosage 
forms [18]. It appears that Aloe vera gel, with polysaccharides as a significant 
component, has the potential unlike several existing penetration enhancers, to 
also provide multifunctional properties in buccal drug delivery systems. These 
multifunctional properties include mucoadhesion, absorption-enhancing, 
sustaining drug release and modified drug release properties.  A buccal 
controlled release product based on Aloe vera gel (AVgel) will therefore be an 
attractive system for the administration of ARV drugs.  
 
The aim of this study was therefore to identify the buccal permeability potential 
of a model ARV drug i.e. didanosine (ddI) in the absence and presence of a 
potential novel buccal permeation enhancer, namely AVgel. In addition the 
study also aimed at evaluating the histomorphological effects of ddI and AVgel 





Materials and Methods 
 
Ethical Clearance 
Ethical approval was obtained from University of KwaZulu-Natal Animal Ethics 
Committee in 2008 (001/08/Animal) and renewed annually in 2009 
(028/09/Animal), 2010 (029/10/Animal) and 2011 (25/11/Animal).  
 
Materials 
Didanosine (ddI) (Chromatographic purity (HPLC) = 99.4 %) was donated by 
Aspen Pharmacare (South Africa). AVgel, in dry powder form, was received 
from the International Aloe Science Council (IASC, 051309, Texas, USA) and 
was the same sample used in our previously reported study in Planta Medica 
[15]. The 1H-NMR spectrum of the AVgel and the quantities of chemical 
markers as determined by NMR spectroscopy are available as supporting 
information (Figure 1S and Table 1S) and are discussed under the Results 
section. Disodium hydrogen phosphate, potassium dihydrogen phosphate and 
sodium chloride were purchased from Sigma-Aldrich (Germany). All other 













Fig. 1S: 1H-NMR spectrum of AVgel labeled with the main chemical 






















Table 1S: Chemical composition of AVgel as determined by 1H-NMR [15] 
 AVgel 
Chemical Content (%) Content 
(mg/L) 
Aloverose 12.7 892.1 
Glucose 16.7 1171.2 
Malic acid 20.0 1403.4 
Lactic acid 5.1 359.2 
Citric acid not detected  
WLM detected  
Maltodextrin not detected  
Acetic acid not detected  
Succinic acid trace  
Fumaric acid not detected  
Formic acid not detected  
Sodium benzoate not detected  




Preparation of Porcine Buccal Mucosae 
Buccal mucosae harvested from pigs (30–40 kg) (Biomedical Resource Unit, 
UKZN) and sacrificed by LECO euthanasia were appropriately excised. The 
thickness of the buccal mucosa was 665±72 μm (CV=8.3%). Fresh buccal 
mucosae were used for histological evaluations. For buccal permeability 
studies, the buccal mucosae were snap frozen in liquid nitrogen, stored in a 




In Vitro Permeation  
Frozen buccal mucosae were allowed to thaw and equilibrated in phosphate 
buffer saline pH 7.4 (PBS). Franz diffusion cells (PermeGear, Inc., Bethlehem, 
USA) with a diffusional area of 0.786 cm2 were used for permeation 
experiments. The buccal mucosa was mounted to the diffusional area between 
the donor and receptor cells and was equilibrated with PBS at 37 °C. The donor 
compartment contained either varying concentrations of ddI in PBS alone (5, 
10, 15 and 20 mg mL-1) or ddI (20 mg mL-1) in the presence of AVgel (0.25, 
0.5, 1.0, 2.0, 4.0 and 6.0 %w/v). The receptor compartments were filled with 
PBS. Samples were removed from the receptor compartments at 
predetermined time intervals and replaced with the same volume of ddI–free 
PBS. Each experiment was undertaken using a minimum of three replicates. 
Similar to permeation studies with other drugs [19, 20], ddI was quantified by a 
validated UV Spectrophotometry method at a λmax of 250 nm (UV 
Spectrophotometer 1650, Shimadzu, Japan).  
 
Permeability Data Analysis  
The cumulative amount of ddI permeated per unit surface area was plotted 
against time. The steady state flux (Jss) was determined from the linear part of 
the permeability curve by linear regression analysis (Microsoft Excel 2007, 





   (1) 
 
Where dQ/dt is the cumulative amount permeated per unit time, A is the 
diffusion area and Cd is the drug concentration in the donor compartment. The 
permeability of ddI was evaluated in the presence of various concentrations of 
AVgel. The enhancement ratio (ER) was calculated as follows [21]:  
 
  (2) 
 
 Viscosity Determination  
The viscosities of ddI (20 mg mL-1) only and ddI (20 mg mL-1) in the presence 
of AVgel (0.25, 0.50, 1.0, 2.0, 4.0 and 6.0 %w/v) were determined with a 
Modular Advanced Rheometer (ThermoHaake MARS, Thermo Fischer 
Scientific, Germany), equipped with a titanium cone (C35 / 1° Ti) set at a 
sample gap of 0.051 mm and a Thermocontroller (UTC-MARS II). The 
relationships between the viscosity and shear stress as a function of shear rate 










Light Microscopy and Transmission Electron Microscopy 
Fresh buccal mucosa was cut into 1 x 1 x 0.1 cm cross sections. Mucosae were 
incubated in bottles containing either PBS only, or ddI/PBS (20 mg mL-1) or 
ddI/PBS (20 mg mL-1) / AVgel in varying concentrations. The bottles were kept 
in a water bath at 37 °C over six hours. Untreated buccal mucosa was 
transferred from normal saline into 10% buffered formalin without incubation in 
PBS and served as the control. Both the control and treated buccal mucosae 
were fixed in formalin for seven days. Buccal mucosa was dehydrated using 
an ethanol gradient and embedded in paraffin wax. The sections were collected 
on slides, dried and stained with Hematoxylin and Eosin (H&E). Semi-thin 
sections (1 µm) of the epoxy-embedded samples were also obtained and 
stained with Toluidine Blue. Sections were examined using a light microscope 
(Nikon 80i, Japan) and bright field images were captured using NIS Elements 
D software and a camera (Nikon U2, Japan).  
 
Samples for transmission electron microscopy (TEM) were incubated as 
described above. Samples were cut into pieces not exceeding 0.5 mm3, and 
fixed for 24 hours (4°C) using Karnovsky’s fixative [22] buffered to pH 7.2. 
Samples were processed and embedded in epoxy resin using standard 
protocols. Ultrathin sections (90 nm) were cut and contrasted with uranyl 
acetate and lead citrate and viewed with a transmission electron microscope 




All experiments were performed using a minimum of three replicates. 
 
Statistical Analysis 
The results, expressed as Mean ± standard deviation (SD), were analyzed 
using One-way ANOVA followed by Mann Whitney test using GraphPad 
Prism® (Graph Pad Software Inc., Version 3). Differences were considered 
significant at p < 0.05.  
 
Results and Discussion 
The permeability potential of ddI in the absence of an enhancer was initially 
investigated. Fig. 1 shows the cumulative amount of ddI permeated at different 
donor concentrations. The flux values increased with an increase in ddI 
concentration and ranged from 25.94±1.35 μg cm-2 hr-1 to 71.57±3.12 μg cm-2 
hr1 (Table 1). There was a significant difference  (p=0.001) between all 
concentrations except between the flux values of 15 mg mL-1and 20 mg mL-1 













Fig. 1: Cumulative amount of ddI permeated per unit surface area vs. time 
profiles observed for ddI donor concentrations (Mean values ± SD; N ≥ 3). 
 
The faster and non-linear drug release observed at earlier times as compared 
to slower and linear drug release thereafter may be due to lack of equilibration 
between the mucosal absorption site and the permeating drug molecules.  
Once an equilibrium exists between the drug molecules and the mucosa, the 
non-linearity disappears due to reservoir of permeating molecules created from 
the partitioning of the drug into the deeper mucosal layers, which slows the 
diffusion rate, hence the slower kinetics observed in this study (Niccolazzo et 
al 2003; Mashru et al 2005; Birudaraj et al 2005). 
A linear relationship (R2=0.9557) between the flux and ddI concentrations was 








































transport across the buccal mucosa [23, 24]. Didanosine is hydrophilic and its 
passive diffusion should favour the paracellular pathway [25, 26].  
 
Table 1: Effect of ddI donor concentration on its permeability parameters 
Donor 
Concentration 






















(P) x10-2   
(cm hr -1) 








0.52 ± 0.03 








0.49 ± 0.09 








0.38 ± 0.04 








0.36 ± 0.02 
 
 
Xiang et al [3] highlighted the promising potential of zalcitabine (ddC), the only 
other ARV reported to date for buccal delivery. They reported a flux of 
13.42±6.35 μg cm-2 hr-1for ddC at 20 mg mL-1 which is lower than the flux of 
ddI (71.57±3.12 μg cm-2 hr-1 ). Several drugs with similar and lower flux values 
have been reported as having the potential for improving drug therapy via the 
buccal route [23, 24, 27]. ddI may therefore be regarded as having the potential 






Fig. 2: Effect of donor concentration on the steady state flux of ddI at pH 
7.4 (Mean values ± SD; N ≥ 3) 
 
The AVgel employed in this study to investigate its effect on ddI permeation 
was the same as used by Chen et al. [13] to study its effects on intestinal drug 
permeability. The 1H-NMR spectrum of the AVgel is shown in Fig. 1S and the 
quantities of chemical markers as determined by NMR spectroscopy in Table 
1S. The results indicate that the AVgel material contained all the essential 
markers especially aloverose.  
 
The buccal permeability of ddI in the presence of AVgel (Fig. 3) was 
investigated. The flux of ddI in the absence of AVgel was 71.57±3.12 μg cm-2 
hr-1. It increased significantly (p<0.001) with an increase in AVgel concentration 
y  =  3.491x + 6.032





























Donor Concentration of ddI (mg mL-1)
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up to 2 %w/v (Table 2), which demonstrated the highest permeability coefficient 
of 3.3 x 10-2 cm hr-1 and an enhancement ratio (ER) of 11.78, thereby 





Fig. 3 Cumulative amount of ddI permeated per unit surface area vs. time 
profiles observed for AVgel concentrations (Mean values ± SD; N ≥ 3). 
 
The permeation enhancing potential of AVgel from 0.25 to 2.0 %w/v may be 
similar to proposed mechanisms for other polysaccharides reported as 
permeation enhancers [28]. Polysaccharides such as chitosan are known to 
demonstrate mucoadhesivity, which causes prolonged drug retention on 










































interactions with the epithelial barrier that may weaken it, partially dismantling 
the extracellular matrix structure and intercellular joint. Since the major 
component of AVgel is polysaccharides [18], a similar mechanism may apply. 
Furthermore, AVgel is cationic and its possible ionic interaction with sialic acid 
residues on the buccal mucosae could alter membrane permeability [25, 28]. 
 










* Flux  
(Jss) 
(µg cm-2 hr-1) 
Permeability 
Coefficient (P)  
x 10-2 (cm hr-1) 
Enhanceme
nt 
Ratio  (ER) 
0.0 0.89 71.57 ± 
3.12a 
0.36 ± 0.02 1 
 
0.25 0.99 364.69 ± 
92.59b 
1.82 ± 0.46 5.09 
 
0.5 0.89 613.69 ± 
292.49b 
3.07 ± 1.46 8.58 
 
1.0 0.85 650.07 ± 
164.41b 
3.25 ± 0.82 9.08 
 
2.0 0.88 842.73 ± 
129.24b 
4.21 ± 0.65 11.78 
 
4.0 0.95 83.95 ± 
11.71c 
0.42 ± 0.06 1.17 
 
6.0 0.99 62.02 ± 
5.41c 
0.31 ± 0.03 0.87 
 
 
*[(a vs b; p < 0.05), (a vs c; p> 0.05)];    aflux of the control;     bstatistically significant 
higher than control (ANOVA); cstatistically non-suignificant compared to control 
 
Further increases in AVgel to 4.0 and 6.0 %w/v led to a decrease in flux to 
83.95±9.24 and 62.06±5.58 μg cm-2 hr-1 respectively. Although there is a 10 
fold reduction in the flux between 2 and 4 %w/v AVgel, the flux at 4 and 6 %w/v 
is reduced to a value which is statistically similar to the flux in the absence of 
  
 134 
AVgel (Table 3). The decrease may be attributed to a higher viscosity of AVgel 
at higher concentrations that can increase resistance to drug diffusion and 
hinder drug movement [18, 29]. Increasing the concentration of AVgel in the 
ddI/PBS/AVgel formulations led to an increased viscosity of the formulations 
(Fig. 4) and displayed a linear correlation (R2=0.972). The viscosity of AVgel at 
6.0 %w/v (2.84 mPa) was almost three times (up to 240%) higher than that at 
0.25 %w/v (0.94 mPa) (Table 3). The viscosities of AVgel at 4.0 and 6.0 %w/v 
may have been high enough to impede the buccal permeability enhancing 
potential of AVgel. Similar trends, with an initial increase in flux with increase 
in enhancer concentrations (propylene glycol) but resultant flux decreases with 
further increases have been reported in another study [30], although possible 
reasons were not investigated.  
 
Table 3: Effect of AVgel concentration on the viscosity of 
ddI/PBS/AVgel formulations 








0 0.84 ±0.00 0 
0.25 0.94 ±0.05 12.19 
0.5 1.05 ±0.01 25.14 
1 1.22 ±0.04 45.51 
2 1.86 ±0.52 121.89 
4 2.21 ±0.14 163.38 




The ER of ddI increased approximately 12-fold with AVgel 2.0 %w/v, but 
decreased to 0.87-fold with AVgel 6.0 %w/v (Table 2). The ER values in this 
study are within the range of previous studies using AVgel at similar 
concentrations for other routes. The ER for colchicine through porcine skin was 
11.2 (AVgel 3.0 %w/v) [17] while that of insulin through the intestinal epithelial 
monolayer was 2.31 (2.5 %w/v AVgel) [13]. A higher ER at a slightly lower 
concentration of 2 %w/v is reported for the buccal mucosa in this study. One 
explanation is that the buccal mucosa is more permeable than skin. Also, 
insulin in the previous study is a larger molecule, and may not permeate to a 
similar extent as ddI. The ER of other buccal enhancers were found 
comparable to those observed with AVgel in this study. Other chemical 
enhancers such as sodium glycodeoxycholate (ER=32), menthol (ER=2.02) 
and sodium glycolate (ER=9) have been reported as effective enhancers for 
buccal delivery [3, 21].  
 
Fig. 4: Effect of AVgel concentration on the viscosity of ddI/PBS/AVgel 







































While permeation enhancing effects of substances are extensively reported, 
their effects on buccal mucosa morphology are limited [3, 31]. Since buccal 
delivery involves retention of a delivery system on the mucosae, an 
assessment of histological effects of a drug and or enhancer/s to evaluate their 
suitability is essential.  
Histomorphological effects of the control/untreated and the treated porcine 
buccal mucosae (PBS alone and ddI/PBS in the absence and presence of 
AVgel) were assessed. The morphology of pig buccal mucosa has been 
described previously and it closely resembles human buccal epithelium [32, 
33]. In the control group the buccal epithelium resembled that of a normal non-
keratinized stratified squamous layer (Fig. 5a). Basal cells appeared oval and 
darkly stained in H&E (Fig. 5b) and toluidine blue (Fig. 5c) sections, reflecting 
their greater mitotic activity. The middle region showed large polygonal cells 
and superficial cells showed desquamation (Fig. 5d). Basal cells were 
nucleated while some of the superficial cells were anucleate. The basal cell 
layer represents the germinal tissue from which new cells are produced and 
should form the focus of such studies. Damage to superficial layers can be 
rectified by renewed growth from the germinal layer, but chronic or severe 
damage to the basal cell layer is probably irreversible [34]. The appearance of 
the control, PBS and ddI/PBS samples in H&E (Figs 5a-b) and toluidine blue 
(Figs 5c-e) respectively, were similar suggesting no influence of PBS or ddI 
(either alone or in combination) on tissue morphology. Therefore, ddI at the 
highest concentration had no adverse effects on the buccal mucosae.  
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The buccal mucosa upon treatment with ddI/PBS in combination with AVgel 
was examined. The addition of 0.5 %w/v AVgel led to an increase in 
intercellular spaces and darker staining of the cytoplasm, resembling the 
structure of control samples (Fig. 5f). However, increased AVgel concentration 
to 1%w/v showed a marked increase in intercellular spaces and distortion of 
cellular outlines (Fig. 5g). Cells appeared irregular and crenulated compared 
to controls. This was accentuated in 6 %w/v AVgel samples where extreme 
compaction of cells in the basal region was observed (Fig. 5h).  Although not 
shown, cells from the middle and superficial layers also appeared severely 
damaged. Furthermore, the epithelial surface and basal lamina of the mucosa 
in the H&E sections of the control, PBS alone, ddI/PBS and ddI/PBS/AVgel 0.5 
%w/v still appeared intact after six hours, but extensive disordering of this cell 
layer was observed in toluidine blue sections of the ddI/PBS/AVgel 6 %w/v. 
This disorder increased towards the epithelial surface, and may be due to the 











Fig. 5: Microphotographs of the control and treated buccal mucosal 
sections for Light Micrsoscopy (LM); stained with H&E: (a) control / 
untreated, (b)ddI/PBS, and with toluidine blue: (c) control/untreated, (d) 
PBS, (e) ddI/PBS, (f) ddI/PBS/AVgel 0.5 %w/v, (g) ddI/PBS/AVgel 1.0 %w/v,  
(h) ddI/PBS/AVgel 6.0 %w/v 
 
The ultrastructure of buccal mucosae was evaluated. The control buccal 
mucosae showed short profiles of endoplasmic reticulum, an abundance of 
ribosomes and regular nuclei with evenly-dispersed chromatin (Fig. 6a).  
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Mitochondria appeared dense with well-developed cristae suggesting normal 
cellular activity (Fig. 6b). Intercellular spaces were small and clearly defined 
desmosomes between attachment plaques in neighbouring cells were 
observed (Fig. 6c). PBS and ddI/PBS treated mucosae showed a similar 
ultrastructure to the saline control, confirming trends observed at light 
microscope level. Cells from 0.5 %w/v AVgel samples also showed signs of 
active cellular metabolism and regular nuclear outlines (Fig. 6d). While electron 
translucent clearings within the mitochondria were occasionally observed, 
cellular damage was not evident (Fig. 6e). However, increasing AVgel 
concentration to 1 %w/v led to cellular damage evident by irregular nuclear 
outlines, peripheral distribution of visibly-compacted chromatin, electron-lucent 
mitochondria containing little internal detail and distended endoplasmic 
reticulum profiles (Fig. 6f).  Increased intercellular spacing and crenulation of 
the plasmalemma also became evident (Fig. 6g). Further increases in  AVgel 
concentrations to 2 and 6 %w/v led to disruption of basal cell layers, severe 










Fig. 6: Microphotographs of the control and treated ultra-thin buccal 
mucosa sections for transmission electron microscopy (TEM): (a) control / 
untreated, (b) PBS, (c) ddI/PBS, (d-e) ddI/PBS/AVgel 0.5 %w/v (f-g) 

















Histomorphological evaluations showed that AVgel caused adverse effects on 
the mucosa at higher concentrations of 1, 2 and 6 %w/v. Since the buccal 
mucosa was not adversely affected at lower concentration of 0.5 %w/v, AVgel 
may therefore be considered as a safe permeation enhancer up to this 
concentration. At 0.5 %w/v, AVgel showed an ER of 5.09 which is still higher 
than several other reported enhancers [3, 23, 27].   
 
The study has shown that ddI can permeate the buccal mucosa without 
adversely affecting its morphology. AVgel at concentrations up to 2 %w/v was 
identified as an effective buccal permeation enhancer for ddI. Based on the 
findings; it is proposed that AVgel be used in concentrations at or lower than 
0.5 %w/v due to adverse mucosal effects at higher concentrations. 
Histomorphological evaluations therefore proved useful in correlating the 
permeation enhancing properties of AVgel with its effects on the buccal 
mucosa. The results confirm the potential of developing a buccal drug delivery 
system containing ddI and AVgel as an enhancer for improving drug therapy. 
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Table 1S: Chemical composition of AVgel as determined by 1H-NMR [15] 
 AVgel 
Chemical Content (%) Content (mg/L) 
Aloverose 12.7 892.1 
Glucose 16.7 1171.2 
Malic acid 20.0 1403.4 
Lactic acid 5.1 359.2 
Citric acid not detected  
WLM detected  
Maltodextrin not detected  
Acetic acid not detected  
Succinic acid trace  
Fumaric acid not detected  
Formic acid not detected  
Sodium benzoate not detected  









Fig. 1S: 1H-NMR spectrum of AVgel labeled with the main chemical 
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The aim of this study was to explore the potential of novel oleic acid (OA) 
derivatives as buccal permeation enhancers for the delivery of didanosine (ddI). 
The OA derivatives, i.e. ester derivative (OA1E), the dicarboxylic acid derivative 
(OA1A) and the bicephalous dianionic surfactant (OA1ANa) were synthesised 
and their permeation effects were compared to the parent OA.  OA, OA1E, OA1A 
and OA1ANa at 1 %w/w all showed potential for enhancing the buccal 
permeability of ddI with enhancement ratio (ER) of 1.29, 1.33, 1.01 and 1.72 
respectively. OA1ANa at 1 %w/w, demonstrated the highest flux (80.30 ± 10.37 
µg cm -2.hr), permeability coefficient (4.01 ± 0.57 x 10 -3 cm hr-1) and enhancement 
ratio (1.72). The highest flux for ddI (144.00 ± 53.54 µg cm -2.hr) was reported 
with OA1ANa 2 %w/w, which displayed an ER of 3.09 more than that with ddI 
alone. At equivalent concentrations, OA1ANa (ER=3.09) had a significantly 
higher permeation enhancing effect than its parent OA (ER=1.54). 
Histomorphological studies confirmed that OA1ANa at all concentrations except 
6.0 %w/w had no adverse effects on the mucosae. Morphological changes such 
as vacuoles formation and increased intercellular spaces were attributed to the 
buccal permeation enhancing effect of OA1ANa. This study demonstrated the 
potential of novel OA derivatives as buccal permeation enhancers. OA1ANa at 2 
%w/w was also identified as the optimal novel OA derivative to widen the pool of 
fatty acid derivatives as chemical permeation enhancers for buccal drug delivery.  






The buccal mucosa remains an attractive alternate and non-invasive site for 
the delivery of both locally and systemically active drugs 1,2.  It avoids the 
degradation of drugs by both the GI acids and enzymes and also bypasses 
hepatic first pass metabolism, thereby improving the systemic bioavailability of 
various drugs3-5. Furthermore, absorption following administration via the 
buccal route is not influenced by potential variations in the gastric emptying 
rate or the presence of food6. The permeability of the buccal mucosa is also 
higher than that of skin 7. Hence, a lower loading dose in a transbuccal device 
could provide the same therapeutic effect as a transdermal patch. The buccal 
mucosa also has a larger area for drug application and has good accessibility 
compared to other mucosae such as the nasal, rectal and vaginal mucosae7. 
Various classes of drugs including zalcitabine (ddC) (antiretroviral)8,9, 
piroxicam (non-steroidal anti-inflammatory)10, morphine (opiate)11, omeprazole 
(proton-pump inhibitor)12, insulin (anti-diabetic hormone and blood gloucose 
lowering agent)13  and metoprolol (beta blocker)14, have been studied for 
delivery via the buccal mucosa to exploit its above advantages. The buccal 
route therefore has wide applicability for diverse drugs and disease conditions.  
 
One of the main challenges with buccal mucosal therapy is its limited mucosal 
permeability due to the epithelial lining of the membrane which acts as a barrier 
to drug permeation 15. The outermost layer of the stratified squamous 
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epithelium is keratinized, covered by a thin layer of mucus and is comparatively 
thicker than the rest of the oral mucosal lining. The basement membrane lies 
directly underneath the epithelium, followed by the lamina propria and the 
submucosa. The mucosa is made up of about 40-50 cell layers and a thickness 
of 500–800 µm has been reported16,17. The mucosal structure thus contributes 
to the challenges and factors that are responsible for the limited buccal 
permeability of drugs.  Enhancing permeation of drugs across the buccal 
mucosa is therefore critical for optimising bioavailability of various drugs 5. 
Maximising the bioavailability of several drugs after buccal administration for 
absorption through the mucosal lining will be beneficial to reducing intra and 
inter subject variability as well as side effects of the drugs 14,18. Moreover, the 
cost of manufacture will be reduced by decreasing drug wastage owing to its 
low systemic bioavailability 19, especially where drugs have limited permeability 
and subsequently low bioavailability. Hence, the use of permeation enhancing 
strategies in many cases is essential to overcome the limited permeability of 
the buccal mucosae for improved buccal drug delivery20,21.  Recent 
advancements in the use of permeation enhancing strategies have identified 
various approaches, including physical and chemical methods, to enhance the 
buccal permeability of drugs. It has been reported that chemical permeation 
enhancers (CPEs), for example bile salts, surfactants and fatty acids (FAs), 
have proved promising for enhancing buccal permeability of drugs22,23. Other 
approaches include drug particle size reduction24, ultrasound and electrical 
assisted approaches (iontophoresis and electroporation) as well as thermal 
enhancement25-27. More specifically, recent reports are emerging on the use of 
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derivatives of common chemical enhancers for further maximising mucosal 
drug permeation. For example, newly synthesised propanoyloxy derivatives of 
5b-cholan-24-oic acid were more effective in enhancing permeation of 
theophylline as compared to its parent compound, cholic acid, thereby 
potentiating the efficacy of bile acids as a class of chemical permeation 
enhancers 28,29. There is therefore a need to explore and identify new 
derivatives of chemical enhancers to widen the pool of available superior 
enhancers for buccal drug delivery. 
 
Fatty Acids (FAs) are widely used chemical permeation enhancers for various 
drugs 17. Sodium caprate, caprylic acid, sucrose esters and lauric acid have 
been reported for enhancing the permeation of drugs such as lidocaine, 
ergotamine, insulin and sumatriptan across the buccal mucosa 23,30-33. It has 
been reported that FAs can disrupt the lipid bilayer of the mucosal lining 
thereby increasing drug transport and bioavailability. Oleic acid (OA) in 
particular has been reported as  an effective chemical permeation enhancer for 
drugs such as levothyroxine sodium  via the intestinal route 34, caffeine and 
diclofenac sodium (DS) via the transdermal route 35 and 5-fluorouracil via the 
buccal route 1. Novel derivatives of OA will therefore be useful for further 
improving their permeation enhancing potential and will contribute to the pool 







In a previous study by our group, the synthesis of novel OA derivatives, known 
as oleodendrimers A1E, A2E, E1E and E2E were reported. Additionally, the 
potential of these derivatives as transdermal permeation enhancers for the 
delivery of a non-steroidal anti-inflammatory drug, diclofenac sodium were 
identified 36. These derivatives, A1E, A2E, E1E and E2E are G1 and G2 Janus 
type dendrimers in which the dendron moiety is linked with OA through ester 
and amide bonds. Oleodendrimers A1E and A2E have an amide linkage 
whereas E1E and E2E have an ester linkage between the dendron and OA 
moiety. This study showed the OA derivatives, oleodendrimers, as being far 
more effective in enhancing the transdermal permeation of diclofenac sodium 
as compared to the parent OA. The specific mechanism of permeation 
enhancement was not cited in the previous study. However, as fatty acids, it 
could be proposed as the perturbation /disruption of the lipid bilayer of the 
stratum corneum which could have led to increased drug permeation across 
the epidermis of the skin 23  
 
The potential of these novel oleodendrimers as permeation enhancers for 
buccal drug delivery has not been studied for any drug to date. The buccal 
permeation enhancement probability of the OA derivatives can expand its 
applicability in drug delivery systems. Therefore, in this study it was decided to 
explore the potential of the oleodendrimer E1E (OA1E), its dicarboxylic acid 
derivative (OA1A) and a sodium salt of dicarboxylic acid (bicephalous dianionic 
surfactant, OA1ANa) as buccal permeation enhancers. OA1E has been 
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studied previously as a transdermal enhancer only and derivatives OA1A and 
OA1ANa have not been studied as permeation enhancers for any drug by any 
route. 
 
In the previously reported study, OA1E was synthesised by methods that 
involved the use of hazardous reagents such as thionyl chloride, harsh reaction 
conditions involving high reaction temperatures and it was furthermore a 
detailed multistep process 37.  In keeping with the current trends of applying 
green chemistry approaches 38, the synthesis of the OA1E derivative, from 
which OA1A and OA1ANa are obtained, by a modified method to eliminate the 
above drawbacks will be beneficial for its commercial application as enhancers 
for various routes.  
 
In this study, didanosine (ddI) was selected as a model drug for in vitro buccal 
permeation investigations. Antiretroviral (ARV) drugs have improved the 
treatment of Human Immunodeficiency Virus (HIV) infection and Acquired 
Immune Deficiency Syndrome (AIDS), diseases that significantly affect the 
global population 39,40. Most ARVs, including ddI, have low bioavailability due 
to the first pass effect and gastrointestinal acidic and enzymatic degradation. 
Additionally, they exhibit dose-dependent toxicities and adverse effects 41,42. 
ARV drugs such as ddI may therefore benefit from buccal delivery. The 
permeability potential of ARV drugs via the buccal route has been investigated 
for ddC, ddI, TFV, AZT and SQV 7,9,43-45 and these ARVs have all shown 
potential for permeability via the buccal mucosa. There are limited studies on 
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the identification of chemical permeation enhancers for ARV drugs. The latter 
have included polymeric excipients 44, aloe vera 43, bile salts 9 and menthol 8.  
 
The aim of this study was therefore to synthesise novel OA derivatives by a 
greener chemistry approach and explore the potential of OA and its 
oleodendrimer derivatives as novel permeation enhancers for buccal 
permeability using ddI as a model ARV drug. 
 
 
2. Materials and Methods 
2.1. Ethical Clearance 
Ethical approval (Reference 039/13/Animal) was obtained from the University 
of KwaZulu-Natal Animal Research and Ethics Committee. 
 
2.2. Materials  
Oleic acid (OA) (technical grade, 90 %), N-Ethyl-N’-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDAC.HCl), p-
dimethylaminopyridine (DMAP) were obtained from Sigma, USA. 3-Amino-1-
propanol and tert-butyl acrylate were purchased from Alfa-Aesar (USA). 
Acetyl chloride (AcCl) and dichloromethane (DCM) were from Merck Chemicals 
(Germany). All other solvents used were of analytical grade and were procured 
from Merck Chemicals (Germany). Merck precoated Silica-gel 60F254 plates 
were used for thin layer chromatography. Didanosine (ddI) [Chromatographic 
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purity (HPLC) = 99.4 %] was purchased from Ruland Chemistry Co., Ltd 
(Nanjing, China). Disodium hydrogen phosphate (Na2HPO4), potassium 
dihydrogen phosphate (KH2PO4), sodium chloride (NaCl) and hydroxypropyl 
methyl cellulose (HPMC) were purchased from Sigma-Aldrich (Germany). 
Sodium Hydroxide (NaOH) and Hydrochloric Acid (HCl) were of analytical 
grade. Milli-Q Purified water was obtained from the purification system 
(Millipore Corp., USA) in our laboratories. Pigs (40 - 60 kg) were supplied by 
the Biomedical Resource Unit, UKZN (South Africa). 
 
2.3  Methods  
2.3.1 Synthesis and characterisation of OA Derivatives 
2.3.1.1 Synthesis  
The synthetic scheme in Figure 1 shows the reaction sequences involved in 
the synthesis of the different, three OA derivatives used in this study 37,46 i.e. 
ester derivative, oleodendrimer E1E (OA1E), the dicarboxylic acid derivative 
(OA1A) and the bicephalous dianionic surfactant (OA1ANa). The derivatives, 
i.e. OA1E, OA1A and OA1ANa as well as their molecular mass, formulae and 













Figure 1: Scheme showing the reaction sequences involved in the 
synthesis of different OA derivatives. 
 
2.3.1.1.1 Synthesis of 3-N, N-di- (tert-butyloxycarbonylethyl) aminopropanol 2 
 
Compound 2 was synthesised following the literature procedure.   Briefly, to a 
solution of tert-butyl acrylate (19.2 g, 1.5 mol) in MeOH (200 ml), 3-amino-1-
propanol 1 (3.75 g, 0.5 mol) in MeOH (100 ml) was added drop wise 
maintaining the reaction temperature below 30 oC. The reaction mixture was 
allowed to stand overnight after stirring at room temperature for 8 h. The 
solvent (MeOH) and excess tert-butyl acrylate were removed under vacuum to 











Table 1: Molecular Mass, Formula and chemical structure of ddI and OA, 




2.3.1.1.2 Synthesis of Oleodendrimer E1E (OA1E) 4 
A mixture of compound 2 (2.84 g; 0.90 mol) and DMAP (0.68 g, 0.56 mol) in 
DCM (25 ml) was stirred at room temperature for 10 minutes. To this mixture 
EDAC.HCl (2 g, 1.12 mol) was added followed by a mixture of OA (2 g, 0.75 







ddI 236.23  C10H12N4O3 
 
OA 282.46  C18H34O2 
 
OA1A 483.36 C27H49NO6  
 
 
OA1ANa 527.32 C27H47NNa2O6  
 




for 48 h. Solvent was evaporated under vacuo and crude product obtained was 
purified by column chromatography using silica gel # 60-100 mesh with 
hexane/EtOAc, 9:1 as an eluent to obtain compound 4 as a colorless liquid 
(3.84 g, 91 %). 
 
2.3.1.1.3 Dicarboxylic acid derivative of OA (OA1A) 5 and its sodium salt 
(OA1ANa) 6 
Literature reported procedures 37 with slight modifications were followed for the 
synthesis of compound 5 and 6. In short, to a mixture of compound 4 (5.95 g, 
0.01 mol), H2O (0.72 g, 0.04 mol) in DCM (100 ml), acetyl chloride (3.14 g, 0.04 
mol) was added drop wise, over a period of 10 min and stirred for 8 h. The 
reaction mixture was washed with brine water and concentrated in vacuo after 
drying over anhydrous Na2SO4 to afford compound 5 as a viscous liquid (3.98 
g, 82 %). This compound 5 was utilised, without further purification, for the 
preparation of compound 6. In short, a solution of 5 (5 g, 0.01 mol) in acetone 
(200 ml) was neutralised with 20 % hot aqueous NaHCO3 solution (8.35 ml, 
0.019 mol) under vigorous stirring for 2 h. The precipitated white solid was 
further dried by removal of solvent under vacuum to afford compound 6 as an 
off white solid (5.30 g, 97 %). 
 
2.3.1.2 Characterisation of Derivatives 
The synthesised derivatives were characterised by standard analytical 
techniques for structural confirmation. FT-IR spectra were recorded using a 
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Bruker Alpha spectrophotometer (Germany). 1H NMR and 13C NMR were 
recorded using a Bruker NMR instrument (Germany) operating at 400 and 100 
MHz respectively. HLB and log Poctanol/water values of the OA derivatives were 
calculated using ChemSW® software (ChemSW Inc., Version 6.33, California, 
USA). The chemical structures, molecular formulae and mass of the derivatives 
are as presented in Table 1. 
 
2.3.2 Buccal Permeation studies 
2.3.2.1 Formulation and preparation of Gels for Permeation Studies 
To determine the effect of OA and its derivatives, simple gels containing ddI (2 
%w/w), HPMC (4 %w/w), OA and its derivatives (OA1A, OA1E and OA1ANa) 
were prepared using 1 %w/w of either OA or each of the derivatives. The 
compositions of the prepared gel formulations, in the absence of the enhancers 
and in the presence of either OA or its derivatives are described. Briefly, HPMC 
(4 %w/w) was weighed and mixed in a beaker with sufficient quantity of purified 
water.  Also, ddI (2 %w/w), weighed was separately mixed with a small quantity 
of purified water and added to the HPMC. The gel formulation was then made 
up to weight with further purified water, and then stirred on a magnetic stirrer 
until all dissolved and was coded as formulation F1. Each enhancer, i.e. OA, 
OA1A, OA1E and OA1ANa was separately weighed and added to formulation 
F1 at a concentration of 1 %w/w to form the drug / enhancer gels, and were 
coded as formulations F2, F3, F4 and F5 respectively. For the concentration 
effects experiments, the compositions of the prepared formulations are 
described. Briefly, ddI gel in the absence of the enhancers (i.e. OA and its 
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derivatives) was prepared as per formulation F1. OA at varying concentrations 
of 0.5, 1.0, 2.0, 4.0, 6.0 %w/w were weighed, and separately incorporated with 
a sufficient quantity of formulation F1 to make the required formulations F6, F7, 
F8, F9 and F10 respectively. Similarly, OA1ANa in varying concentrations of 
0.5, 1.0, 2.0, 4.0, 6.0 %w/w, was each added to a sufficient quantity of 
formulation F1 to make formulations F11, F12, F13, F14 and F15 respectively. 
Each prepared formulation was stored in an airtight amber container.  
 
2.3.2.2 Preparation of Porcine Buccal Mucosae 
Porcine buccal mucosa has many similarities to the human buccal mucosa and 
was chosen as the biological membrane for the permeation experiments 47-49. 
Pigs were sacrificed using the standard operating procedure at Biomedical 
Resource Unit, University of KwaZulu-Natal (BRU, UKZN). Briefly, the pig was 
weighted and appropriate drugs were mixed to form a cocktail for intramuscular 
injection, by the registered, licensed veterinary doctor at BRU, UKZN. The 
cocktail contained  the following drugs, i.e. Domitor ® (Zoetis, Australia), which 
contains  medetomidine 1mg/ml and dosed at 0.06 mg/kg; Zoletil ® 100 (Virbac, 
Mexico), which contains a mixture of tiletamine 50 mg/ml; zolazepam 50 mg/ml, 
and dosed at 1.5 mg/kg and lastly, Butorphanol 10 mg/ml, (V-Tech Dispensing 
Pharmacy, South Africa) dosed at 0.17 mg/kg. The appropriate, measured 
doses per kilogram body weight of these drugs were each placed in a sterile 
vial and subsequently mixed together and then drawn up into a single 5 ml 
syringe. The pig was restrained by placing it in a squeeze cage and the cocktail 
was injected into the quadriceps muscle. The ear vein became easily 
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accessible within 5-7 minutes such that the pig was at a stage of sedation and 
free of pain. The pig was then euthanized with Eutha-Naze® (Bayer, South 
Africa), containing sodium pentobarbitone 200 mg/ml, dosed at 1 ml/kg and 
administered intravenously at a rapid rate. Generally a state of death was 
achieved with about 10-15 ml of Eutha-Naze. Buccal mucosae harvested from 
euthanized pigs, were appropriately excised and prepared for the permeation 
experiments. The thickness of the buccal mucosa was 665±72 μm (CV=8.3%).  
For buccal permeability studies, the buccal mucosae were wrapped in foil, 
snap-frozen in liquid nitrogen and then stored in a bio freezer (-85 °C) until 
further use within three months according to previous reports 20,50.  
 
 
2.3.2.3   In Vitro Permeation  
Frozen buccal mucosae were allowed to thaw and equilibrated in phosphate 
buffer saline pH 7.4 (PBS). Franz diffusion cells (PermeGear, Inc., Bethlehem, 
USA) with a diffusional area of 0.786 cm2 were used for permeation 
experiments. The buccal mucosa was mounted to the diffusional area between 
the donor and receptor cells and was equilibrated with PBS at 37 °C. Initially, 
just the ddI gel, in the absence of any enhancer (formulation F1) and presence 
of OA and the oleodendrimer derivatives, i.e. OA1A, OA1E and OA1ANa; 
formulated at only one gel concentration as formulations F2, F3, F4 and F5 
respectively were employed in the permeation experiments. Briefly, the donor 
compartment contained either ddI (2 %w/w) / HPMC (4 %w/w) gel alone, or in 
the presence of 1 %w/w of either OA or its oleodendrimer derivatives (OA1A, 
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OA1E and OA1ANa). In the subsequent experiments, i.e. the concentration 
effect studies, ddI gel in the presence of either OA or OA1ANa, at varying 
concentrations, 0.5, 1.0, 2.0, 4.0 and 6.0 %w/w; was placed in the donor 
compartment. The receptor compartments were filled with PBS. Samples were 
removed from the receptor compartments at predetermined time intervals and 
replaced with the same volume of PBS (drug–free). Each experiment was 
undertaken using a minimum of three replicates. ddI was quantified by a 
validated UV Spectrophotometry method at a λmax of 250 nm (UV 
Spectrophotometer 1650, Shimadzu, Japan) as employed by  previous buccal 
permeation studies with antiretrovirals such as ddI 43 and ddC 8,9; as well as 
other drugs including ondasetron 51, galantamine 52 and carbamazepine 53.  
 
2.3.2.4 Permeability Data Analysis  
The cumulative amount of ddI permeated per unit surface area versus time was 
plotted. The steady state flux (Jss) across the mucosal membrane was 
determined from the linear part of the permeation graph by linear regression 
analysis (Microsoft Excel® 2010, USA). The permeability coefficient (P) was 
calculated using the following equation 8: 
 
𝑃 = (𝑑𝑄/𝑑𝑡  )/𝐴 𝑥 𝐶𝑑 = 𝐽𝑠𝑠 / 𝐶𝑑                                                  (1) 
 
Where dQ/dt is the cumulative amount (Q) of ddI permeated per unit time (t), 
A is the active, cross-sectional diffusion area and Cd is the drug concentration 
in the donor compartment. The effects of OA, OA1A, OA1E and OA1ANa and 
  
 168 
the various concentrations of OA and OA1ANa on the permeability of ddI were 
evaluated. The enhancement ratio (ER) was calculated using the following 
equation 8: 
 
𝐸𝑅 = 𝑃 (𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑟)/ 𝑃 (𝑁𝑜 𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑟)    (2) 
 
2.3.2.5 Morphological Evaluations using Light Microscopy and 
Transmission Electron Microscopy  
Histological evaluations were performed on freshly harvested, excised buccal 
mucosa. Untreated buccal mucosa was transferred directly after excision from 
normal saline into 10% buffered formalin without any equilibration in PBS and 
served as the control. Treated samples of the buccal mucosae comprised of 
those that were exposed to PBS only, or ddI gel formulation with and without 
OA1ANa at varying concentrations of 0.5, 2.0 and 6.0 %w/w. Permeation 
experiments were performed as described in previous studies, without drug 
quantification 25,43,51. At the end of the permeation experiments, the buccal 
mucosa was cut into cross sections. For light microscopy (LM), the samples 
were fixed in 10% buffered formalin for seven days, washed in water, 
dehydrated using an ethanol gradient and embedded in paraffin wax using 
previously described standard procedures 20,43,50.  The sections were collected 
on slides, dried and stained with Hematoxylin and Eosin (H&E). Sections (in 1 
µm thick slices) were examined using a light microscope (Nikon 80i, Japan) 
and bright field images were captured using NIS Elements D software and a 




The samples for Transmission Electron Microscopy (TEM) were obtained after 
the permeation experiments described above. They were cut into pieces not 
exceeding 0.5 mm3, and fixed for 24 hours (4°C) using 4 % glutaraldehyde 
fixative, buffered to pH 7.2  54. Samples were processed and embedded in 
epoxy resin using standard protocols. Ultrathin sections (90 nm) were cut and 
contrasted with uranyl acetate and lead citrate and viewed with a transmission 
electron microscope (JEOL 1010, Japan). All experiments were performed 
using a minimum of three replicates. 
 
2.3.2.6  Statistical Analysis 
The results, expressed as mean ± standard deviation (SD) in values, were 
analysed using one-way analysis of variance (ANOVA), and followed by a 
Tukey’s Multiple Comparison Test using GraphPad Prism® (Graph Pad 
Software Inc., Version 5). Differences were considered significant at p < 0.05.  
 
3 Results and Discussion 
 
3.1 Synthesis and Characterisation of Novel Oleodendrimer Derivatives  
The OA derivatives, i.e. ester derivative (OA1E), the dicarboxylic acid 
derivative (OA1A) and the bicephalous dianionic surfactant (OA1ANa) were 
successfully synthesised by a modified method that excluded harsh reaction 
conditions in keeping with the current trends of greener approaches to synthetic 
chemistry. The literature reported procedure for the synthesis of OA1E from 
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which OA1A and OA1ANa were subsequently derived in this study 46 required 
a high reaction temperature and the use of thionyl chloride, a hazardous 
chemical. In the present work, the synthetic methodology was successfully 
modified by the use of coupling agents, viz., DMAP and EDAC.HCl. This 
synthetic modification enabled the avoidance of thionyl chloride to transform 
OA into oleoyl chloride, synthesis at room temperature instead of 110 oC as 
well as a reduction in the number of steps involved in the synthesis of OA1E 
and the other OA derivatives.  
 
The structures of the newly synthesised compounds by the modified method 
were confirmed by 1H NMR and 13C NMR spectroscopic analysis and 
compared to the spectroscopic data for the OA derivatives synthesised by the 
original method from the literature 46. The data below show that the compounds 
were identical to the compounds prepared by the previously reported method 
37,46. Therefore the modified method in line with green chemistry approaches 
could be used to successfully prepare the OA derivatives. 
 
a)  3-N,N’-di-(tert-butyloxycarbonylethyl)aminopropanol (compound 2) 
1H NMR (CDCl3) δ: 1.44 (s, 18 H), 1.72 (q, 2H), 2.42 (t, 4H), 2.64 (t, 2H), 2.77 
(t, 4H), 3.75 (t, 2H). 
b)  OA1E (compound 4) 
1H NMR (CDCl3) δ: 0.89 (t, 3H), 1.30 (m, 20H), 1.44 (s, 18H), 1.63 (q, 2H), 1.77 
(m, 2H), 2.04 (m, 4H), 2.34 (m, 6H), 2.49 (t, 2H), 2.73 (m, 4H), 4.09 (t, 2H), 
5.35 (m, 2H). 13C NMR (CDCl3) δ: 14.10, 22.67, 24.98, 26.65, 27.20, 27.89, 
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28.09, 29.18, 29.31, 29.51, 29.70, 29.75, 31.89, 33.76, 34.34, 49.38, 50.13, 
62.43, 80.31, 129.74, 129.97, 171.96, 173.85. 
c) OA1A (compound 5) 
1H NMR (CDCl3) δ: 0.89 (t, 3H), 1.30 (m, 20H), 1.45 (s, 18H), 1.64 (m, 4H), 
1.77 (m, 2H), 2.01 (m, 6H), 2.35 (m, 6H), 2.95 (m, 4H), 3.32 (m, 4H), 4.16 (t, 
2H), 5.34 (m, 2H), 6.25 (br s, 2H). 13C NMR (CDCl3) δ: 14.10,    22.67, 24.82, 
27.15, 27.21, 29.06, 29.14, 29.31, 29.51, 29.58, 29.67, 29.76, 31.89, 33.99, 
48.53, 50.68, 55.40, 60.93, 129.72, 130.02, 173.56, 179.50. 
 
 
3.2 In-vitro Buccal Permeation 
3.2.1 Effects of OA, OA1E, OA1A and OA1ANa as permeation enhancers 
on the buccal permeability of ddI 
 
In this study, the permeability enhancement potential of OA and its 
oleodendrimer derivatives, i.e. OA1A, OA1E and OA1ANa as novel buccal 
permeation enhancers to enhance the buccal permeability of ddI is reported. 
The cumulative amounts of ddI permeated over six hours, its in vitro 
permeation parameters in the absence of any enhancer and in the presence of 
either OA or the novel oleodendrimer derivatives, i.e. OA1A, OA1E and 
OA1ANa are shown in Figure 2 and Table 2 respectively. The flux of ddI in the 
absence of any of the enhancers was 46.57 ± 10.15 µg cm -2.hr. This flux was 
marginally increased to 60.08 ± 10.34 µg cm -2.hr in the presence of OA, the 
parent compound with ER of 1.29 although the increase was not statistically 
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significantly different from that of the control (p = 0.0674).  The flux values for 
ddI in the presence of OA derivatives) i.e. OA1A, OA1E and OA1ANa were 
46.57 ± 4.93 µg cm -2.hr, 61.88 ± 9.75 µg cm -2.hr and 80.30 ± 10.37 µg cm -2.hr  
respectively with ER values of 1.01, 1.33 and 1.72 respectively. Therefore, 
these OA derivatives were able to enhance permeation of ddI, with OA1E and 
OAIANa specifically having higher ER values than the parent OA itself.  
OA1ANa with an enhancement ratio (ER) of 1.72 had the highest permeation 
enhancing effect as compared to OA, OA1A and OA1E. Statistical analysis 
showed a highly significant difference (p = 0.0004) between the flux with 
OA1ANa when compared to the control (ddI without any enhancer). A highly 
significant difference was also observed between OA1ANa when compared to 
OA1A (p<0.0001) as well as to OA (p<0.0001). Moreover, there was an overall 
significant difference (p = 0.0116) between the permeability enhancing efficacy 
of OA1A and OA1E when compared with OA1ANa (Table 2). In comparisons 
to other studies, the permeability enhancements obtained in this study were 
consistent with data from the previously published literature sources with oleic 
acid enhancers. The buccal mucosal permeability of Fluorouracil in a gel 
formulation incorporated with oleic acid as an enhancer, was increased by 1-6 
fold as compared to gels without enhancer 1,55,56. However, lower permeability 
values have been reported where oleic acid was used for drug permeability 
enhancement across the transdermal route 57,58. In a recent study reported on  
OA’s enhancing effect on diclofenac sodium (DS), OA enhanced the 
transdermal permeation of DS (ER = 1.87) 36. This is comparable to the ER 




Figure 2: The effect of OA, OA1E, OA1A and OA1ANa on the cumulative 
amount of ddI permeated across the buccal mucosae. 
 
Drugs generally can use either the paracellular or transcellular pathways or 
both for permeating the lipoidal membrane, and enhancement across the 
buccal mucosa 59,60. Hydrophilic drugs in particular can permeate the lipoidal 
membrane via the paracellular route. FAs as chemical permeation enhancers 
can improve the permeability of drugs via the paracellular pathway 60. It has 
been postulated that OA enhances permeability of drugs across the membrane 
by disrupting the lipid structure of the membrane, causing solubilisation by 
formation of micelles to create aqueous channels. One other probable 
mechanism is that FAs cause extraction of the inter- and intra-cellular lipids 
and proteins of the membrane 31, thereby causing an increased fluidity in the 
membrane. Various reasons could be attributed to the observed permeation 
enhancement differences between the OA1ANa and the other two derivatives. 
With available literature findings on percutaneous and oro-mucosal permeation 









































and the experimental observations in this study, a discussion to correlate the 
structural effects of OA derivatives on the permeation of ddI through porcine 
buccal mucosa is presented. The chemical structures, molecular mass, HLB, 
Log Po/w and ERflux for the novel derivatives, are shown in Tables 1 and 3. The 
basic structural difference in the three OA derivatives is that OA1E has a 
branched diester function, OA1A is a dicarboxylic acid and OA1ANa is a 
bicephalous dianionic surfactant. These structural differences of OA 
derivatives along with their physicochemical properties are taken into 
consideration to correlate structural effects on buccal permeability. Based on 
this, OA1E showed higher ER as compared to OA1A which can be attributed 
to the higher lipophilicity of OA1E than OA1A 37. The results correlate with 
previous findings where it has been observed that an increase in lipophilicity 
results in an increase in transdermal permeation of diclofenac sodium 36.  Also 
OA1E has a branched tert-butyl ester function at its periphery which may have 
contributed to enhanced ddI permeation since the branched diesters can 
provide better permeation enhancement 61. OA1ANa showed the highest ER 
amongst all the three derivatives although less lipophilic. Its higher ER as 
compared to the other 2 derivatives may be due to a combination of effects. It 
may be due to its amphiphilic nature and surfactant characteristics which O1AE 
and OA1A lack. Like other surfactants such as sodium lauryl sulphate, 
OA1ANa might have showed effects like, disorganisation of the entire 
membrane architecture due to the extraction of the inter- and intra- cellular 
lipids and proteins of the membrane; the expansion of intercellular spaces, and 
the insertion of OA1ANa molecules into the lipid structure 62 which facilitated 
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better permeation of the drug through the lipid bilayer. These results are in 
good agreement with previous studies where oral mucosal absorption of 
lidocaine significantly increased in the presence of a surfactant derived from 
fatty acid 63. In addition to the disruption of the lipid bilayer by the FAs, the 
sodium derivative could have an added advantage of ionic interactions 
between the free Na+ ions and the negatively charged sialic acid residues of 
mucin on the mucosae that may have further altered the membrane 
permeability 64. This is proposed as an additional mechanism since in contrast, 
OA1A and OA1E are acidic and ester compounds respectively and lacked the 
Na+ ions that may have caused the ionic interaction between sialic acid and the 
enhancer as in OA1ANa.  Furthermore, similar interactions have been reported 
in previous studies where interaction of the enhancer with the sialic acid 
residues has been proposed as a mechanism of permeation enhancement, i.e. 

















Table 2: Permeability parameters of the OA, OA1A, OA1E and OA1ANa 
as novel buccal permeation enhancers for ddI (Mean ± SD; n ≥3) 
{“a versus b” demonstrates statistically non-significant difference (p > 0.05), 
in the flux values of the enhancers compared to the control}. 
{“a versus c” demonstrates statistically significant difference (p < 0.05), in 
the flux values of the enhancers compared to the control}. 
 
 The enhanced transbuccal permeation of ddI in the presence of OA1ANa is 
therefore presumably attributed to the disruption of the lipid bilayer as well as 
the ionic interaction between the sodium ions and sialic acid of the mucosal 
lining. 
It has been reported that the log P values and HLB number can play an 
important role in differentiating enhancement ratios, flux and permeability 
coefficient values 28. Moreover, it has been shown that the ester derivatives 
have better enhancement potential than the acid derivatives 36. HLB and 
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OA1A 345.98  


































hydrophilicity order of OA derivatives was OA1ANa > OA1A > OA1E (Table 3). 
Significant increase (p < 0.05) in ERflux with OA1ANa (ERflux =1.72) was 
observed than with OA1E (ERflux = 1.33). From this observation it can be 
concluded that an increase in HLB value and hydrophilicity of OA derivative 
due to conversion into a surfactant molecule, resulted in increased ERflux of ddI 
with OA1ANa. However, ERflux value with OA1A was lower than with OA1E 
though the HLB and hydrophilicity of OA1A was more than OA1E. These 
contrasting results may be due to the fact that OA1E and OA1A as lipidic 
structures act by the same mechanism of action like other FA derivatives 61 and 
OA1ANa as a surfactant also acts by a mechanism of action similar to other 
surfactant like molecules 63. It should be noted that the difference in ERflux of 
OA1A and OA1E was not significant (p >0.05). 
 
Table 3: Log Poil/water, HLB and ER flux of the OA derivatives, i.e. OA1E, OA1A and 
OA1ANa 
Derivative HLB Log Poctanol/water ERflux 
OA1E 4.79 9.40 1.33 
OA1A 7.41 6.00 1.01 






The faster and non-linear drug release observed at earlier times as compared 
to slower and linear drug release thereafter may be due to lack of equilibration 
between the mucosal absorption site and the permeating drug molecules.  
Once an equilibrium exists between the drug molecules and the mucosa, the 
non-linearity disappears due to reservoir of permeating molecules created from 
the partitioning of the drug into the deeper mucosal layers, which slows the 
diffusion rate, hence the slower kinetics observed in this study (Niccolazzo et 
al 2003; Mashru et al 2005; Birudaraj et al 2005). 
Another observation is that there was no lag time in the permeation profiles 
obtained for the enhancing effect of OA and its derivatives on ddI permeability 
(Figure 2). By nature of the permeation enhancing effect of the enhancers, the 
cell layers would have been disrupted, hence reducing and/or removing any 
lag time that the drug might experience. Furthermore, as ddI is hydrophilic, 
permeation may be via the paracellular pathway thereby further reducing the 
lag time despite the thickness of the mucosae. Similar lack of lag times during 
buccal permeation studies on various drugs including didanosine, lidocaine 
and tenofovir, using porcine buccal mucosa has been reported previously 
24,43,44,63 
 
In this study, it has therefore been shown that OA and its novel derivatives, i.e. 
OA1E, OA1A and OA1ANa, to a different extent enhanced the buccal 
permeability of ddI. The oleodendrimer derivative OA1ANa further had the 





3.2.2 Effects of varying concentrations of OA and OA1ANa on the 
buccal permeability of ddI. 
The above study identified OA1ANa as having the highest permeation 
enhancing effect.  The effects of varying concentrations of the OA1ANa 
derivative was then studied and compared to OA (Figure 3 and Table 4). This 
study also identified the concentration range at which it will be effective and 
potentially safe for buccal permeation enhancement of ddI. The permeation 
enhancing potential of OA1ANa, as shown by the permeability properties of 
ddI, increased significantly (p = 0.0014) from 0.5 %w/w (ER = 1.14) to 2 %w/w 
(ER = 3.09), but decreased at 4 %w/w (ER = 1.55)  and at  6 %w/w (ER = 1.50). 
Similar trends in the permeability properties of ddI in the presence of OA1ANa 
were also observed for OA at varying concentrations (Figure 3 and Table 4). 
Increase in OA1ANa concentrations from 0.5 to 2 %w/w led to increasing ER 
values but further increases at 4 and 6 %w/w led to subsequent decreases in 
ER values and they did not show any further enhancement in the ddI flux; and 
this was similarly observed for OA. Interestingly, the highest flux of ddI was 





























The results obtained in this study are similar to previous studies where 
increasing the concentration of the enhancers increased the buccal 
permeability enhancement initially, but further increases in concentration led to 
decreased permeability 31,43,57. Reasons for the trend observed could be due 
to disruption of the lipid bilayer of the buccal mucosa occurring at the 2 %w/w 
concentration to allow for optimum permeation, whilst increased concentrations 
to 4 and 6 %w/w could have increased the viscosity at the mucosal layer, 
resulting in low drug movement 65. Higher concentrations may have also 
decreased partitioning of ddI from the gel. Previous studies that used OA as a 
permeation enhancer have reported that the flux of piroxicam in the presence 
of OA increased from 0.3 %w/w to 1 %w/w but decreased at 5 %w/w 57. The 
reason attributed to this was that at a 5  %w/w OA concentration, the presence 
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of a large amount of the FA could have slowed down the partitioning of the drug 
out of the gel base, thereby reducing the permeability rate of piroxicam 57. The 
maximum ER value for OA1ANa obtained (ER=3.09) is similar to and in some 
cases higher than other reported CPEs stated as being promising enhancers 
for buccal permeation e.g. 3.2 for propylene glycol and dodecyl-2-
dimethylamino propionate (DDAIP) HCl with ondasetron 25 and 1.8 for sodium 
dodecyl sulphate with caffeine 66. It has been previously shown that the novel 
derivative, OA1E, used in this study could enhance the transdermal permeation 
of drugs 36. The ER of the OA1ANa derivative compares with the 
oleodendrimers reported in that study. The ER ranged from 2.02 to 2.58 for 
oleodendrimers with the amide linkage. Interestingly, these ER values for 
transdermal permeation (2.02 to 2.58) are lower than the ER values obtained 
for OA1ANa (ER = 3.09). This can be due to the higher permeability of the 
buccal mucosa than that of the skin; since the skin unlike the buccal mucosa 
is keratinized and the application site in the skin layers could be thicker and 
greater thus posing more challenges for drug permeability7.  Additionally, 
possible interaction of the Na+ ions with negatively charged sialic acid residues 










Table 4: Effects of concentrations of OA and OA1ANa on the Permeability 
parameters of ddI (Mean ± SD; n ≥3) 
 Cum Amt 
Permeated,  
Q6Hr   (µg.cm -2) 
Flux, Jss 
(µg cm -2 .hr) 
Enhancement 
Ratio (ER) 
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This study has identified for the first time a novel derivative of OA, OA1ANa, as 
an effective buccal permeation enhancer, thereby adding to the pool of 








3.3  Light Microscopy (LM) and Transmission Electron Microscopy 
(TEM) for the Histomorphological Evaluations of the mucosa 
Permeation enhancers can play a role in the improvement of the permeability 
of drugs; however their suitability needs to be established as they may have 
membrane damaging effects 8,67. Buccal delivery involves retention of the drug 
delivery system on the buccal mucosal site for diffusion to occur across the 
mucosa. Hence, the basal membrane of the mucosa must remain intact to 
ensure an effective diffusion of the drug. LM and TEM have been used in the 
literature to assess integrity of and histomorphological changes on the buccal 
mucosae after drug permeation studies 43,44,68.  
 
In this study the effects of OA1ANa, being the buccal permeation enhancer 
amongst the three OA derivatives studied with the highest permeability 
coefficient and flux values, were investigated using LM and TEM. It must be 
noted that the barrier function of the stratified epithelium lends itself to a 
‘rebound’ effect after prolonged exposure to a drug, which was not assessed 
in this study. However, adequate information can be obtained from LM and 
TEM images to determine whether the tissue suffered permanent/irreversible 
damage after exposure to the drug and enhancer treatment 64,68.  
The morphology of the porcine buccal mucosa has been described previously 
and its characteristics resemble that of the human buccal epithelium49,69. The 
LM and TEM treated sections were compared to the controls. In LM 
investigations, the untreated mucosae/controls resembled that of a normal 
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non-keratinized, stratified squamous layer and the basal cells appeared oval 
and darkly stained in H&E (Figure 4A). Hence, the cells observed in the control 
sections could be regarded as healthy cells. The cells observed in the ddI gel 
treated mucosae (Figure 4B) resembles those seen in the control, therefore 
confirming that ddI gel and the excipients in the formulation did not adversely 
affect the mucosa.  
 
The cells of the mucosa treated with ddI+ OA1ANa 0.5 %w/w   (Figure 4C) 
closely resemble that of the control (Figure 4A) and the ddI gel treated 
mucosae (Figure 4B). This shows that no adverse effect was displayed in the 
cells of the mucosa treated with OA1ANa 0.5 %w/w. Moreover, the appearance 
of the control, ddI and ddI+ OA1ANa 0.5 %w/w mucosal sections were all 
similar suggesting that no adverse influence of ddI or OA1ANa at 0.5%w/w in 
the tissue morphology was evident. The outermost layer of the stratified 
squamous epithelium, basement membrane, lamina propria and submucosa 
were all intact in both the treated and untreated mucosae (Figures 4A-4E).  
Therefore OA1ANa 0.5 %w/w had no adverse effect on the buccal mucosae. 
There were no morphological changes observed in the mucosae treated with 
ddI alone (Figure 4B) and those treated with ddI+OA1ANa 0.5%w/w (Figures 
4C). The superficial, prickle and basal cells all remained intact and no loss of 
the superficial cell layers and no formation of vacuoles in both the prickle and 




However, the neatly aligned cells observed in Figures 4A and 4B which are the 
control and ddI gel treated mucosae respectively appeared to be interspaced 
in Figures 4C-4E which are ddI+OA1ANa 0.5 %w/w, ddI+OA1ANa 2 %w/w and 
ddI+OA1ANa 6%w/w treated mucosae respectively. The increased 
intercellular spaces (Figures 4C-4E)) could be attributed to the permeation 
enhancing effect of OA1ANa. Furthermore, the intercellular spaces between 
the epithelial cells increased with an increase in the concentration of OA1ANa 
from 0.5 %w/w to 2 %w/w, and further increased with ddI+OA1ANa 6%w/w 
(Figures 4C-4E). Moreover, swellings and vacuoles formation were observed 
in the prickle layers of the enhancer-treated mucosae compared to the control 
and drug-treated mucosae. When compared to the ddI+OA1ANa 0.5%w/w 
treated mucosae, increased formation of vacuoles, swelling and increased 
intercellular spaces in both the basal and prickle cell layers were observed in 
the ddI+OA1ANa 2 and 6 %w/w treated mucosae (Figures 4D-4E). The 
progressive morphological changes observed in treated cells could therefore 
explain the increased permeation of ddI observed in this study with OA1ANa 
at these concentrations (Figure 3). Increase in swelling and vacuole formation 
may also be attributable to accumulation of both drug and enhancer in the 
mucosa cells without the loss of the superficial layer. Increasing permeation 
was observed from ddI+OA1ANa 0.5 %w/w to ddI+OA1ANa 2 %w/w which 
correlates with the increased intercellular spaces, formation of vacuoles and 




There were clear distinctions between the cells treated with ddI+OA1ANa 2 
%w/w (Figure 4D) and with ddI+OA1ANa 6 %w/w (Figure 4F). The cells treated 
with 6 %w/w were not as darkly stained as in the control, 0.5 %w/w and 2 %w/w 
treated cells. They showed probable reduced mitotic activity in both the prickle 
and basal layers, which may prevent diffusion of the drug across the basal 
cuboidal cell layer. The partitioning of drug across the biological membrane is 
possibly due to the mitotic activity in the mucosal cells. Thus, if a disruption is 
shown in the cells, such that cell organelles are disorganized, there could be a 
reduced mitotic activity and hence reduced partitioning of drugs 70. Evidence of 
disruption to the cell organelles could indicate lack of partitioning of drugs into 
the membrane, hence lack of drug transport by diffusion across the membrane. 
This slight reduction in the mitotic activity observed in the basal cell layers could 
have led to the reduced permeability observed at the higher concentration 
(ddI+OA1ANa 6 %w/w). With ddI+OA1ANa 6 %w/w treated mucosae, the basal 
cells were additionally not totally oval in shape, showing some distortions in the 
membrane. However, any damage to the mucosa is considered non-
permanent as the mucosa can regenerate from its damaged status by renewed 
growth of the mucosa from the germinal layer 71. The results of this study 
correlated with trends observed in the concentration effect of aloe vera gel on 









(B) (C)  
(D)  (E)  
     
Figure 4:  Photomicrographs of the control (untreated) and treated buccal 
mucosal sections stained with H&E (LM): (A) control /untreated 
(SL: superficial layer; PL: prickle layer; BL: basal layer; CT: 
connective tissue); (B) ddI gel (in the absence of any enhancers); 
(C) ddI + 0.5 %w/w OA1ANa; (D) ddI + 2 %w/w OA1ANa and  (E) 










In TEM investigations, an in-depth ultrastructural analysis of the cellular 
organelles of the buccal mucosa sections is made possible. TEM was therefore 
undertaken to confirm the effect of the novel derivative OA1ANa on the cellular 
organelles of the buccal mucosa that was observed at the LM level and 
reported above. The ultrastructure of the untreated buccal mucosa (control) 
showed regular nuclear profiles with closely packed cellular walls and well-
arranged desmosomes at the gap junctions. The nuclear outlines appeared 
regular in the control buccal mucosal section (Figure 5A).  
Both the ddI and OA1ANa 0.5 %w/w treated mucosae resembled the control 
section by way of their regular nuclear outlines and absence of cellular 
distortions. The mitochondria appeared dense in both the ddI gel treated 
mucosa (Figures Bi-ii) and the OA1ANa 0.5 %w/w treated mucosae (Figure 
Cii), although they showed slight electron translucent clearings within the 
mitochondria. An increase in the intercellular spaces was noted with ddI gel 
only (Figures 5B) as well as ddI+OA1ANa 0.5 and 2 %w/w treated mucosae 
(Figures 5Ci and 5Di). The increased intercellular spaces observed could be 
attributed to the partitioning of the permeant (ddI) as well as the enhancing 
effect of OA1ANa.  
A permeant can use either the paracellular, transcellular or both pathways 
mechanisms for permeability enhancement 7,69. The increase in the 
intercellular spaces did not damage the gap junctions as evident by the 
presence of the desmosomes. Interestingly, the desmosomes appeared intact 
in the ddI+OA1ANa 2 %w/w treated mucosa (Figure 5D (ii)). This may indicate 
that the highest permeability observed at this concentration level could be via 
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the paracellular transport pathway. Surfactants can disrupt the lipid bilayer / the 
entire membrane architecture of the buccal mucosa, cause an expansion in 
intercellular spaces and can lead to an insertion of the OA1ANa molecules into 
the lipid structure 72 which can encourage the enhanced permeability of drugs. 
Though appearing slightly swollen, no evidence of damage to the desmosomes 
at the gap junction could be seen except for increased intercellular spaces. 
This can also be due to the enhancing effect of OA1ANa on the buccal 
permeability of ddI 17. While the nuclear envelope appeared slightly irregular 
as observed in the ddI+OA1ANa 2 %w/w treated mucosa, cellular damage was 
not evident. The nuclear membrane showed slight distortion in the outlines 
which do not differ much from that of the ddI+OA1ANa 0.5 %w/w treated 
mucosae.  However, crenulation of the nuclear envelope was observed in the 
ddI+OA1ANa 6 %w/w (Figure 5E).  
In this study, LM confirmed that there was no adverse effect and no tissue 
damage as a result of the ddI gel when used alone and when in combination 
with OA1ANa 0.5 and 2 %w/w except for the OA1ANa 6 %w/w where adverse 
effects were observed. TEM revealed similar effects of OA1ANa on the mucosa 
as observed with the LM. Since the mucosa was not adversely affected at these 
concentrations, i.e. 0.5 and 2 %w/w, OA1ANa could be used at these 
concentrations to enhance the permeability of ddI. In permeation studies, 
OA1ANa was identified as the enhancer with highest ER for ddI. Based on 
these results, OA1ANa at 2 %w/w can be proposed as an enhancer in a 
delivery system since the exposure of OA1ANa concentrations up to 2 %w/w 
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did not show any adverse effects on the buccal mucosa and simultaneously 
displayed the highest permeability enhancement. 
  
(A)      (Bi) 
  
(Bii)     (Ci) 
  
(Cii)     (Di) 
 
(Dii)       (E) 
 
Figure 5:  Electro-micrographs of the control (untreated) and treated ultra-
thin buccal mucosal sections (TEM):   (A) control /untreated; (Bi 
and ii) ddI gel only (in the absence of any enhancers); (Ci and 
ii) ddI + 0.5 %w/w OA1ANa; (Di and ii) ddI + 2 %w/w OA1ANa; 





The derivatives of OA were successfully synthesised incorporating the use of 
a coupling agent i.e DMAP and EDAC.HCl that eliminated the use of thionyl 
chloride and high reaction temperatures as well as reduced the number of 
synthetic steps. This study clearly demonstrated that OA and its novel 
derivatives, i.e. OA1E, OA1A, and OA1ANa could enhance the buccal 
permeability of ddI. All the novel derivatives of OA that were explored and 
reported in this study increased the buccal permeability of ddI, with the 
OA1ANa derivative having the best enhancing potential than other derivatives 
and its parent compound, OA. OA1ANa 2 %w/w displayed the highest flux and 
permeability for ddI across the buccal mucosa with an enhancement ratio of 
3.09 more than that of the ddI alone. The permeability enhancing effects 
OA1ANa as a novel buccal permeation enhancer for ddI was shown to be 
concentration-dependent. Interestingly, both OA and OA1ANa also showed a 
similar trend with flux values as their concentrations were increased. Maximum 
flux for both OA and OA1ANa were observed at 2 %w/w with ER values of 1.54 
and 3.09 respectively. The morphological changes reported in this study, i.e. 
vacuoles formation, increased intercellular spaces and swelling were attributed 
to, and correlated with the permeation enhancing effect of the novel OA1ANa 
derivative. No adverse effects were observed in all treated and untreated 
mucosae in this study. The novel OA derivatives show potential for the 
enhancement of the buccal permeability of ddI and can widen the pool of 
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The conclusions drawn from the main experimental findings in this study are 
presented in this chapter. It also identifies possible study limitations, and 
highlights the significance of the study as well as recommendations for future 
work.  
 
The potential of the buccal mucosa route to deliver different classes of drugs, 
including antiretroviral, specifically ddI, may overcome certain challenges 
suffered by the current use of other routes, such as oral, parenteral and rectal, 
to increase therapeutic outcomes and patient compliance. A major focus in the 
area of buccal delivery of drugs is identifying approaches to overcome the 
challenges of limited buccal permeability due to the epithelium layer that acts 
as a barrier to drug permeation. Thus, the selection of a safe and effective 
permeation enhancer is essential for the design of buccal drug delivery 
systems to promote the permeation of drugs across the buccal mucosa and 
improve bioavailability. The potential of the buccal mucosa route for delivery of 
ARVs have not been comprehensively investigated.  The ultimate aim of this 
study therefore, was to explore the potential of the buccal mucosal route for the 




The permeation experiments using vertical Franz diffusion cells were 
undertaken, and permeability of ddI across the buccal mucosa was confirmed. 
Histomorphological studies using light and transmission electron microscopy 
to evaluate the effect of ddI and the novel permeation enhancers on the buccal 
mucosa were performed. Furthermore, the preliminary formulation experiments 
were undertaken and reported as published research abstracts. Novel MMFs 
containing ddI for buccal delivery were prepared using homogenization, casting 
and solvent evaporation methods. In vitro dissolution studies of the MMFs 
containing ddI were performed using a shaking water bath. Scanning electron 
microscopy was employed to evaluate the surface morphology of the films 
before and after in vitro dissolution testing. The ddI MMFs prepared in this 
study were confirmed as potential candidates for optimization into buccal 
delivery systems.  
 
 
5.2 CONCLUSIONS FROM THE STUDY FINDINGS 
 
This study purposed to explore the potential of the buccal mucosa route to 
deliver a model ARV drug, i.e. ddI. The study had three sub-aims as presented 
below, and each had a number of objectives. The conclusions drawn from each 





1. Investigate the permeability properties of ARV drugs across the buccal 
mucosa using ddI as a model ARV drug. 
 
 The potential for delivering an antiretroviral drug such as ddI using the 
buccal mucosa as an alternate route was confirmed. The buccal 
permeability parameters of ddI were identified, and the effects of ddI 
concentration study showed that its permeation across the buccal 
mucosa was concentration-dependent. A linear relationship 
(R2=0.9557) between the flux and ddI concentrations indicated that 
passive diffusion was the mechanism of its transport across the buccal 
mucosa. 
 
2. Determine the effects of different novel enhancers such as, AVgel, OA and 
the synthesized oleodendrimer derivatives of OA, on the buccal permeability 
of ddI. 
 
 The effect of AVgel as a buccal permeation enhancer obtained from a 
natural plant product was investigated. The study showed that ddI can 
permeate the buccal mucosa in the absence of AVgel, and without 
adversely affecting the mucosal morphology. AVgel, at concentrations 
0.25 to 2 %w/v, was identified as an effective buccal permeation 
enhancer for ddI. The permeability enhancement potential of AVgel for 
ddI increased significantly from 0.25 to 2 %w/v, with enhancement ratio 
(ER) of 5.09 (AVgel 0.25 %w/v) to 11.78 (AVgel 2 %w/v).  The 
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enhancement of ddI increased approximately 12-fold with AVgel 2.0 
%w/v, but decreased to 0.87-fold with AVgel 6.0 %w/v. Therefore, AVgel 
can increase the permeation of ddI across the buccal mucosa with the 
enhancement being concentration-dependent. 
 
 
 The effects of OA and its novel derivatives were investigated i.e. ester 
derivative (OA1E), dicarboxylic acid derivative (OA1A) and bicephalous 
dianionic surfactant (OA1ANa) as chemical permeation enhancers for 
buccal delivery of ddI. This study clearly demonstrated that OA and its 
derivatives, i.e. OA1E, OA1A, and OA1ANa, all at 1 %w/w, could 
enhance the buccal permeability of ddI. OA and all the novel derivatives 
that were explored and reported in this study increased the buccal 
permeability of ddI, with the OA1ANa derivative having the best 
enhancing potential than other derivatives and its parent compound, 
OA.  
 
 The concentration effect of the best identified oleodendrimer derivative, 
OA1ANa, was also investigated at varying concentrations of 0.5 to 6 
%w/w, and compared with its parent compound, OA. The permeability 
enhancing effects of OA1ANa as a novel buccal permeation enhancer 
for ddI was shown to be higher than its parent compound, OA, and was 
concentration-dependent. OA1ANa at 2 %w/w displayed the highest flux 
of 144.00 ± 53.54 µgcm-2.hr, and enhanced the permeability of ddI 
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across the buccal mucosa with an enhancement ratio of 3.09, more than 
that with the ddI alone.  At equivalent concentrations, OA1ANa (ER = 
3.09) showed higher enhancement of ddI than the parent compound, 
OA (ER = 1.54). This novel OA derivative displayed the best potential 
for enhancing the buccal permeability of ddI, and it can widen the pool 
of chemical permeation enhancers for the buccal delivery of ddI and 
other drugs for therapy optimization. 
 
 
3. Assess the histo-morphological effects of both ddI and the novel enhancers, 
AVgel and OA oleodendrimer derivatives on the buccal mucosa, using light 
and transmission electron microscopical studies. 
 
 Histomorphological investigations of the buccal mucosae in the absence 
or presence of AVgel were performed. This study therefore 
demonstrated that there were adverse effects on the cell organelles of 
the 1, 2 and 6 %w/v AVgel-treated mucosae. However, the cell 
organelles of the buccal mucosae treated with PBS, ddI/PBS and 
ddI/PBS/AVgel 0.5 %w/v were still intact, and showed that there were 
no adverse mucosal effects. Based on the findings in this study, it is 
proposed that AVgel can be used in concentrations at or lower than 0.5 
%w/v due to adverse mucosal effects at the higher concentrations. The 
histomorphological evaluations in this study also proved useful in 
correlating the permeation enhancing properties of AVgel with its effects 
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on the buccal mucosa. AVgel effectively enhanced the buccal 
permeability of ddI at all concentrations studied. A safe and effective 
concentration of 0.5 %w/v w with ER of 5.09 was identified. Therefore 
AVgel at 0.5 %w/v showed the most buccal permeation enhancing 
potential for delivering an antiretroviral, ddI.  
 
 
 Histomorphological investigations of the buccal mucosae in the absence 
or presence of the selected OA derivatives were also performed. Light 
and transmission electron microscopical analysis confirmed that 
OA1ANa at all concentrations, except the 6 %w/v, had no adverse 
effects on the mucosae. Morphological changes, such as vacuoles 
formation and increased intercellular spaces, noted that 2 %w/w were 
attributed to the buccal permeation enhancing effect of OA1ANa.This 
study also showed that OA1ANa is safe and effective to use as buccal 
permeation enhancer for ddI at the identified concentration of 2 %w/v.  
 
 The potential of using AVgel at a concentration of 0.5 %w/v or lower for 
developing a buccal drug delivery system containing antiretroviral ddI 
and buccal permeation enhancer of natural origin. Furthermore, the 
potential of a novel chemical permeation enhancer, i.e. OA1ANa at a 
concentration of 2 %w/v or lower, was identified.  The presence of 
intercellular spaces in the mucosae treated with both ddI and the 
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enhancers suggested that they permeated the buccal mucosa using 
both the paracelular and transcellular routes for transport. 
 
 The findings of this study therefore contributed significantly to knowledge 
about the buccal delivery potential of an ARV, ddI and the permeation 
enhancers of both natural plant and synthetic products origin.  These novel 
enhancers can be selected to develop buccal delivery systems containing 
ARVs, for improving HIV and AIDS therapy. The various ddI MMFs prepared 




5.3 STUDY LIMITATIONS 
 
 
The aim of this study was to explore the buccal delivery potential of an 
antiretroviral drug using ddI as a model drug. The methods employed to 
generate the experimental findings in this study were in line with those 
employed in other studies reported in the literature. However, certain limitations 
as described below should be noted:  
 
 The buccal mucosa, is a biological membrane, and when used for 
permeation studies can produce data with high variability, 
particularly if the membrane is not harvested and excised according 
to an appropriate standard procedures. The initial stage of the 
preparation of buccal mucosae from pigs for permeation 
  
 211 
experiments therefore took extensive time, as very limited expertise 
in the mucosa excision was available in the country. Therefore, much 
time was taken to achieve the correct procedures to obtain the 
buccal mucosa, and to reduce variability in the various permeation 
experiments undertaken at the initial stage of this study. In addition, 
extensive time was taken to ensure that the reported data were 
reproducible. An early exposure to the standard operating 
procedures regarding the preparation of the buccal mucosae, 
including harvesting the mucosae from the pigs, as well as the 
excision for permeation experiments could have saved time, which 
could have been used to add value to the experimental studies. 
 
  Some studies in the literature support permeation studies with 
transepithelial electrical resistance (TEER) which is an indicator for 
epithelial viability and, to demonstrate that mucosal integrity remains 
irreversibly affected. The publication of the findings from 
experimental studies in chapters 3 and 4 could have been improved 
if relevant TEER equipment were available for the study at the initial 
stage. However, the morphological characteristics of the buccal 
mucosae evaluated by LM and TEM as well as the reproducible data, 
did show that the buccal mucosa used in the study remained intact 
throughout the 6 hour experimental period. In addition, the 
permeation data in this study were obtained with acceptable 
standard deviations, and the histomorphological evaluations 
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correlated well with the permeation data. The experimental studies 
on buccal permeability did not include TEER measurements due to 
lack of equipment, which could have further strengthened the 
published paper at the time.  
 
 
 ddI was incorporated into MMFs, and the preliminary experimental 
findings were published as an abstract in an international ISI journal. 
The characterization of the ddI buccal films (i.e. MMFs) in terms of 
drug uniformity content, in vitro drug release, film thickness and 
morphology did confirm the potential for optimization. However, an 
in-depth characterization of the ddI MMFs was not done. Therefore,   
further characterization, such as mucoadhesive and 
physicomechanical properties of the MMFs that were prepared in this 
study, could have strengthened the thesis. This was not performed, 




5.4 RECOMMENDATIONS FOR FUTURE WORK 
 
  
The findings of this study can contribute significantly to the knowledge required 
by formulation scientists to optimally design and formulate ARV buccal delivery 
systems that will incorporate permeation enhancers for improving antiretroviral 
therapy. Further work will be necessary for buccal delivery systems containing 
an ARV such as, ddI, to formulate with permeation enhancers and manufacture 
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for commercialization. Therefore, future research could address the following 
areas: 
 
 The mechanism of ddI permeation in the presence of the enhancers 
should be investigated, as ddI (pKa 9.2) has the tendency to ionize in an 
acidic medium, and any variation in the buccal physiological pH may 
influence the functionality of the dosage form as well as ddI absorption 
mechanism. Therefore, investigating the effect of pH on ddI permeation 
in the presence of the enhancers as well as pH-partitioning studies are 
recommended. Mechanistic studies to characterize the buccal 
permeation properties of both drug (ddI) and enhancers, i.e. AVgel and 
OA1ANa, which would be useful in determining the exact permeation 
pathways are proposed. In addition, molecular dynamics studies on both 
drug and enhancers are proposed in order to predict mechanism of 
permeation, as well as how the molecules of drug and enhancers interact 
with the components of the buccal mucosa. 
 
 The use of conventional light and transmission electron microscopy are 
limited by rigorous method of fixation, sectioning and staining of the 
buccal mucosa. Processing techniques may interfere with the 
examination and interpretation of the structures of the mucosa. Hence, 
confocal scanning laser microscopy is proposed for future studies, as it 
may play a major role in detecting and determining various cell organelles 
in the mucosa. The pathways of the buccal permeation of ddI and the 
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 The enhancers identified in this study have the potential for being 
applicable to other ARVs, particularly the new generation of ARVs, such 
as integrase strand-transfer inhibitors (INSTI, i.e. elvitegravir), and a 
second generation NNRTI, i.e. rilpivirine. It is therefore recommended that 
the study approach described in this thesis be employed in developing 
and optimizing other newer ARVs. The enhancers identified in this study 
can also be investigated for delivery systems containing ddI or any other 
ARV, for various mucosal applications, including rectal and vaginal. 
Furthermore, studies on developing delivery systems that will contain 
more than one drugs for simultaneous delivery via transmucosal routes 
are emerging.  In addition, in South Africa and globally, antiretroviral 
therapy using combination drugs, such as fixed dose combination (FDC) 
of tenofovir, emtricitabine and efavirenz or other multi-class combination 
ARV products, is currently a gold standard treatment for HIV and AIDS in 
an approach referred to as highly active antiretroviral therapy (HAART) 
for improved therapeutics’ outcomes and patient compliance. Therefore, 
an investigation into the effects of the enhancers identified in this study 
for buccal delivery of FDC for other ARVs and multi-class combination 




 Incorporating buccal permeation enhancers into an optimized drug 
delivery system for ddI or other ARVs remains to be investigated. The 
development of a carefully designed advanced buccal delivery system, 
such as nano-composite or polyelectrolyte films, or novel mucoadhesive 
nanoparticles to contain ddI and selected permeation enhancers for 
improved ARV therapy is proposed. Further, optimization and in-depth 
characterization of these delivery systems, in terms of 
physicochemical/mechanical properties, should be explored. Additionally, 
molecular modeling is recommended in order to determine how the 
enhancers will interact with the drug and in the presence of the selected 
excipients. Stability studies on the formulation of ddI MMFs in order to 
ascertain the exact effects of the enhancers on the design and formulation 
of buccal delivery systems, in terms of chemical and physical stability are 
recommended. 
 
 In vivo studies using appropriate animal model, such as pig, to identify 
the effectiveness of the dose of drug and enhancers to be incorporated 
into the buccal delivery systems are proposed. Additionally, the 
acceptability of the buccal delivery systems by the intended human 
populace should be explored. Studies on irritation and toxicity of the drug 







5.5 SIGNIFICANCE OF THE FINDINGS IN THE STUDY 
 
 Optimizing drug treatment of HIV and AIDS: 
 
This study has confirmed the buccal delivery potential of ddI as an 
alternate route for ARV therapy. The treatment of patients suffering 
from HIV and AIDS remains a health priority in South Africa and 
globally. The delivery of ARV drugs via the buccal mucosal route will 
overcome challenges with oral delivery. This study will benefit 
patients in many ways, including increase in bioavailability, reduction 
in systemic side effects of ARVs, and improved patient compliance. 
The delivery of ARV via buccal will benefit patients in many ways, 
including increase in bioavailability due to the highly vascularized 
buccal mucosal site that promote higher absorption of drugs. For 
buccal drug delivery, lower doses are administered compared to the 
high and frequent doses with oral drug delivery, hence the dose-
dependent GI side/adverse effects would be reduced.  Moreover, the 
buccal drug delivery systems may exhibit controlled-release kinetics 
thus decreasing frequency of dosing and reducing systemic side 
effects leading to improved patient compliance, hence optimized 
drug treatment. Identifying alternative route of delivery for ARVs, 
especially in paediatrics and patients with swallowing difficulty is 
paramount for improving ARV therapy. Furthermore, the availability 
of buccal delivery systems containing ddI can increase the variety of 
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dosage forms for various categories of patients, particularly for 
paediatric population. 
 
 Creation of new knowledge in buccal delivery of antiretroviral 
drugs:   
 
This study has identified the buccal permeability parameters of ddI 
and has confirmed the potential of ddI for buccal delivery. It has also 
identified the permeation enhancing abilities and possible 
mechanisms of novel permeation enhancers of both natural plant 
and synthetic origins for buccal delivery. The study also contributed 
to establishing correlations between histological evaluations of 
buccal mucosa using the TEM with permeability parameters in the 
area of ARV buccal delivery.  
 
 Identification of new pharmaceutical  materials for buccal 
delivery: 
 
The project has contributed to the identification of new excipients for 
buccal delivery systems. The identification of synthetic derivatives of 
OA as well as AVgel from natural plant products as enhancers for 
buccal delivery was established. These novel permeation enhancers 
will now be available to formulation scientist for selection in 
formulating, optimizing and manufacturing ddI buccal films for 
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eventual commercialization. This will also be applicable to other 
various classes of drugs for various diseases, and particularly to 
other ARVs, fixed dose combinations, and multi-class ARV 
combinations. Further, the pharmaceutical industries will benefit 
from the findings of this study, in that the newly identified materials 
can be used to manufacture more cost-effective medicines. 
 
 Impact of this study on future research:  
 
The identification of the permeability parameters of the ARV drug, 
ddI as well as drug permeation enhancement potential of AVgel and 
OA derivatives impact on future research as it will stimulate further 
research into the design of ddI buccal delivery systems with optimal 
properties. The findings in this study can also be applied to 
investigate the buccal delivery potential of other newer ARVs, and 
specifically the multi-class combination drugs for improving ARV 
therapy.  This study is also significant for other routes of drug 
administration, such as the vaginal, rectal as well as ocular drug 
delivery routes, as these enhancers may be investigated for these 
routes as well.  
 
The current trend for optimizing drug treatment for various diseases is 
searching for alternate routes for drug delivery, and developing novel drug 
delivery systems, instead of searching for new chemical entities. The buccal 
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mucosa as alternate route for drug administration clearly has potential for the 
delivery of an antiretroviral drug. The design, optimization and evaluation of a 
novel drug delivery system of an ARV for buccal would require multidisciplinary 
collaborative approach and efforts of the researchers in academia, formulation 
scientists as well as pharmaceutical industries. This multidisciplinary 
collaborative approach is particularly warranted for an eventual manufacturing 
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